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GM-CSF Granulocyte macrophage-colony stimulating factor 
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MAPK Mitogen-activated protein kinase 
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PDGF Platelet-derived growth factor 
PDGFR Platelet-derived growth factor receptor 
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RT Reverse transcriptase 
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TBS Tris-buffered saline 
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Malignant melanoma can be well controlled in early stages, but despite new 
therapeutic options, the five-year survival rate decreases down to 9 % in metastatic 
disease. The metastatic propensity of melanoma is a result of the interaction 
between cancer cells and their microenvironment, in which cancer-associated 
fibroblasts and tumor-associated macrophages play an important role. Growth factors 
and cytokines such as transforming growth factor beta 1 and serum amyloid A, 
secreted by tumor and stromal cells, mediate a dynamic crosstalk between these 
cellular compartments. This crosstalk stimulates tumor progression through 
modifying the transcriptional program of those cells. The transcriptional response to 
this crosstalk by cancer-associated stromal cells represents a promising source of 
factors with prognostic or theranostic potential, but this currently remains under-
investigated in melanoma. This thesis therefore assesses the expression of 
transforming growth factor beta 1 and serum amyloid A in melanoma, and asks 
whether the expression of molecules with potential prognostic value might be 
induced in cancer-associated fibroblasts or macrophages in response to these two 
factors. 
 
The expression of serum amyloid A and transforming growth factor beta 1 in primary 
melanoma was investigated by immunohistochemistry and quantitative real-time 
polymerase chain reaction, which showed that both proteins are expressed by tumor 
and stromal cells. Next, the transcriptional response of human dermal fibroblasts and 
monocytic macrophage THP-1 cells to serum amyloid A and transforming growth 
factor beta 1 was assessed. Serum amyloid A upregulated the expression of factors 
implicated in melanoma invasion, matrix remodeling, angiogenesis, immune evasion 
and therapy resistance in THP-1 cells through toll-like receptor 4, including its own 
expression. Transforming growth factor beta 1 stimulated its own expression in 
fibroblasts, as well as that of serum amyloid A and the cancer-associated fibroblast 
marker alpha-smooth muscle actin. Importantly, transforming growth factor beta 1 
upregulated plasminogen activator inhibitor 1 in both fibroblasts and THP-1 cells, 
which was assessed by quantitative real-time polymerase chain reaction and 
enzyme-linked immunosorbent assay. 
Plasminogen activator inhibitor 1 is known as a transforming growth factor beta 1-
inducible molecule that can foster tumor progression through several mechanisms, 
but its potential role as a marker for melanoma has not yet been extensively studied. 
Therefore, this thesis addresses the question of the prognostic potential of 
plasminogen activator inhibitor 1 for melanoma. Increased local protein expression of 
plasminogen activator inhibitor 1 was indeed associated with poor prognosis in 
melanoma patients. Consistently, the systemic levels of transforming growth factor 
beta 1 and plasminogen activator inhibitor 1 positively correlated with each other, 




patients. Further work showed that fibroblasts are an important source of 
plasminogen activator inhibitor 1 in addition to melanoma cells themselves.  
 
Taken together, this thesis shows that melanoma cells condition fibroblasts and 
monocytic macrophages via transforming growth factor beta 1 and serum amyloid A 
to create a tumor promoting milieu. Furthermore, fibroblasts stimulated with 
transforming growth factor beta 1 are an important source of locally overexpressed 
plasminogen activator inhibitor 1, which predicts poor prognosis in melanoma 
patients. Therefore, plasminogen activator inhibitor 1 represents a possible new 






Skin cancer is the most common human malignancy. Although melanoma only 
accounts for 4 % of all skin cancers, it causes the majority of skin cancer deaths1. 
Melanoma is defined as malignancy of the melanocytes, which are neural crest-
derived cells located in the basal epidermis, responsible for the production of melanin 
pigment2. The most common form is cutaneous melanoma, but this tumor can also 
be localized at the mucosa of many organs, the uvea3 as well as the subungual 
space4. Since these three types of melanoma have different biological and clinical 
features5, only melanoma of the skin will be considered here. 
 
The incidence of cutaneous melanoma is rising faster than that of any other solid 
tumor6. From 1999 to 2016, age-standardized incidence rates increased from 12.8 % 
to 20.1 % per 100 000 inhabitants per year in Germany7, and are expected to 
continue rising8. Locally limited melanoma can be well controlled by surgical excision, 
with a five-year survival rate of more than 95 %9. Nevertheless, melanoma is an 
aggressive tumor with high metastatic potential. It is characteristic of melanoma that 
primary tumors of only a few millimeters thickness are able to spread to distant 
organs10. Once melanoma has metastasized, disease management is a lot more 
challenging, and the five-year survival rate decreases down to 9 %9. The interaction 
between melanoma cells and stromal cells of the microenvironment is believed to 
play a crucial role in this metastatic propensity11.  
 
Exposure to ultraviolet radiation (UVR) is considered the major risk factor for the 
development of melanomas12. It causes oxidative damage to base pairs, proteins and 
lipids, but can also be responsible for direct deoxyribonucleic acid (DNA) damage1. 
Photoproducts such as pyrimidine dimers can lead to cancer-initiating mutations if 
they are repaired incorrectly13. Additionally, UVR can cause deletions in 
mitochondrial DNA, leading to mitochondrial dysfunction and cellular energy 
imbalance, which also contributes to photoaging and tumorigenesis14. UVR can also 
act indirectly to promote tumorigenesis. For example, malfunction or apoptosis of 
immune cells can be caused by UVR, which disturbs the endogenous antitumor 
immune control in early melanomagenesis14. In line with this, chronic 
immunosuppression has been found to be a risk factor for the development of 
melanomas15. 
Several oncogenic mutations are associated with melanoma. Of these, those 
affecting the mitogen-activated protein kinases (MAPK) pathway play an important 
role. This pathway regulates cell proliferation, differentiation, migration, senescence 
and apoptosis in response to stress or growth stimuli16. Mutations of the 
serine/threonine-protein kinase B-rapidly accelerated fibrosarcoma (BRAF), that is 




60 % of melanomas17. Mutated BRAF leads to constant, ligand-independent 
activation of the MAPK pathway, resulting in uncontrolled proliferation. After the 
discovery of this driver mutation, targeted anti-BRAF therapies have become 
available for BRAF-mutated patients with metastatic disease, leading to better 
survival. However resistance to treatment often develops, and BRAF inhibitor 
(BRAFi) resistant tumors pose a clinical challenge18. The second most common 
driver mutation is that of the GTPase Neuroblastoma RAS viral oncogene homolog 
(NRAS), which is found in approximately 10 to 15 % of all melanomas17. NRAS 
connects the MAPK pathway to the phosphatidyl-inositol-3-kinase/protein kinase B 
(PI3K/AKT) pathway19, which regulates survival, metabolism, cell proliferation and 
angiogenesis. Mutated NRAS is locked in its active form and therefore permanently 
stimulates both the PI3K/AKT and MAPK pathways20. In melanoma, these mutations 
are associated with more aggressive tumors and poor survival17. To date, there are 
no specific therapeutic approaches against mutated NRAS in melanoma20. 
3.1.1 Prognostic parameters  
Currently, melanoma stages are classified based on the eighth version of the 
American Joint Committee of Cancer (AJCC) staging system21. Stages I and II 
represent the local disease stages with better patient survival. Stage III (lymph node 
metastases, locoregional disease) and IV (metastatic disease) are associated with 
worse prognosis. This classification considers tumor thickness, mitotic rate and 
ulceration of the primary tumor, as well as lymph node status, systemic lactate 
dehydrogenase (LDH) levels and the presence of distant metastases21. The following 
sections address these parameters and also other histopathological features and 
laboratory tests that have prognostic value in melanoma. 
 
The histopathological criterion of tumor thickness is measured from the stratum 
granulosum of the epidermis to the deepest level of tumor invasion, and is also called 
the Breslow index22. However, as there are also thin tumors with high metastatic 
potential and poor prognosis, or thick but noninvasive tumors with better prognosis, 
this parameter does not always reflect patient outcome23. Additionally, ulceration 
status of the primary tumor is also linked to a higher risk of melanoma-associated 
deaths and is part of the current classification system21. Another histopathological 
feature of melanoma (not included in the AJCC staging) is the infiltration of the 
primary tumor by immune cells. The communication between melanoma and immune 
cells plays an important role in melanoma initiation and progression24, but not all 
mechanisms have been elucidated yet. For instance, the infiltration by lymphocytes 
has been associated with good prognosis by some researchers, but also with poor 
outcome by others. This was dependent on the growth phase and the thickness of 
the tumor25. However, the presence of tumor-infiltrating macrophages in melanomas 
is clearly linked to poor prognosis26. 
 
Several predictive markers can be determined in the peripheral blood of melanoma 




patients with suspected or proven metastasis as a part of the staging21. This 
intracellular enzyme can be found in nearly every cell type and catalyzes the 
conversion of lactate to pyruvic acid (and back) in anaerobic glycolysis27. Since LDH 
levels can indicate enhanced cell turnover28, systemic LDH levels are used as an 
indicator for tumor burden in many different cancers27. In cutaneous melanoma, this 
represents a cost-effective parameter to predict worse patient survival in late stages. 
Additionally, LDH levels can also be used to monitor therapy response29. 
Nevertheless, systemic LDH remains an unspecific parameter, since it is also 
elevated in other malignancies23 or in various nonmalignant conditions that result in 
enhanced cell turnover (e.g. infarction, inflammation, infection or hemolysis28). 
Another biomarker is the S100 calcium-binding protein S100B, which was first 
detected in melanoma cell lines30. Its systemic elevation was found to correlate with 
advanced clinical stage31, worse survival and metastasis28. However, brain and non-
melanoma skin tumors have also been reported to produce S100B31, and false 
positive results have been observed in patients with hepatic or renal insufficiency or 
infectious diseases28. Additionally, the predictive value of systemic S100B levels 
seemed to be restricted to stage III and IV melanoma patients31, and the 
measurement of S100B is only conclusive if lymph node or distant metastases are 
suspected or diagnosed21. 
 
In conclusion, various parameters are used to predict melanoma patient outcome, 
focusing on molecules that are produced by tumor cells. However, the tumor 
microenvironment as a potential source of prognostic molecules has been under-
investigated so far. 
3.1.2 Treatment 
Depending on the stage and the biological features of the tumor, different therapy 
options are available. At stage I to III, an excision with safety margin is the standard 
procedure. For in situ-melanomas, this margin is 0.5 cm. For tumors with a thickness 
of up to 2 mm, a margin of 1 cm is required, while for tumors above 2 mm thickness, 
the margin is 2 cm21. Sentinel lymph node biopsy (SLNB) is recommended for 
primary tumors of 1 mm thickness or above without evidence of lymph node or 
distant metastases21. SLNB is considered to offer accurate information about patient 
prognosis, but remains controversial since there is little evidence regarding its 
therapeutic benefit32.  
 
As 20% of melanoma patients undergoing surgical resection will still develop 
metastases33, adjuvant systemic therapy is recommended. At stage I and II, systemic 
administration of interferons (IFN) can be considered21. Interferon-alpha 2b (IFN-α 
2b) activates antitumor T cells and natural killer (NK) cells. It also inhibits myeloid-
derived suppressor cells and regulatory T cells (Tregs)18, that dampen the activity of 
the latter immune cells25, 34. Hence, IFN therapy increases the activity of immune 
cells that are able to eliminate melanoma cells. Frequent systemic side effects are 




therapy with IFN-α 2b improved survival and decreased the risk of recurrence in a 
current meta-analysis35, but only few patients responded to this therapy36. 
At stage III, when lymph node metastases are present, the excision procedure 
described above followed by a lymph node dissection represent the standard of care. 
Adjuvant radiation therapy of the suspect lymphatic drainage basin and/or lymph 
nodes is also recommended when certain criteria are met. 
 
As soon as there are distant metastases (stage IV), surgery should only be realized if 
a complete resection is achievable, if it will not lead to inacceptable functional deficits 
and if other therapies were not or might not be successful21. 
Various possibilities for pharmacological intervention are available at advanced 
melanoma stages. For example, IFNs can be considered. Additionally, from stage 
IIIB on, it is recommended to test for the occurrence of a driver mutation such as 
BRAF, that can be subject to a targeted therapy21. Approximately 90% of stage IV 
patients undergoing BRAFi therapy initially responded with tumor regression37. The 
BRAFi vemurafenib improved overall and progression-free survival of melanoma 
patients compared to the formerly used chemotherapeutic agent dacarbazine37. 
Nevertheless, BRAFi therapy in melanoma is limited by the emergence of therapy 
resistance caused by different mechanisms38. Reasons for BRAFi resistance include 
the expression of an altered BRAF protein and de novo mutations of other molecules 
in the MAPK or PI3K/AKT pathways by the malignant cells (e.g. of Mitogen-activated 
protein kinase kinase (MEK) 1/2, NRAS or AKT1)18. Furthermore, stromal cells can 
also play a role in BRAFi resistance, which will be discussed in more detail later. 
Thus, a combination of BRAF inhibition together with MEK inhibition is currently 
recommended for BRAF mutated patients21. 
In addition to targeted therapy, immune checkpoint inhibitors represent a promising 
therapeutic option for metastatic melanoma patients. Cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) is an inhibitory receptor that blocks T cell responses 
and induces immunotolerance. The blockade of CTLA-4 with ipilimumab resulted in T 
cell proliferation, cytokine production and infiltration of antitumor immune cells into 
melanomas18. In a clinical trial, approximately 20 % of melanoma patients responded 
to ipilimumab39. However, 10 % suffered from severe adverse effects including colitis, 
skin reactions and endocrinopathies40. Anti-CTLA-4 therapy did not increase overall-
survival, but led to better progression-free survival when combined with 
chemotherapy41. 
Another molecule for immune checkpoint inhibition is programmed cell death 
protein 1 (PD-1). It is present on the surface of T cells, binds to programmed cell 
death 1 ligand 1 (PD-L1) on antigen-presenting cells (monocytes/macrophages, B 
cells and dendritic cells), and acts as a co-inhibitory stimulus for T cells. Additionally, 
PD-L1 can be expressed by tumor cells, enabling them to inhibit the activity of 
potential antitumor T cells42. PD-1 inhibition with nivolumab or pembrolizumab 
therefore activates cytotoxic T cells against malignant cells. Response rates to 
nivolumab in melanoma were approximately 44 %39, and PD-1 inhibitors showed 
lower rates of severe adverse effects compared to anti-CTLA-4-antibodies38. 




survival compared to chemotherapy in a recent Cochrane review41. Since 13 % of 
patients with PD-L1-negative tumors still profited from PD-1 blockade43, testing PD-
L1 expression is not considered necessary before the application of PD-1 inhibitors23. 
Therefore, as an alternative to the combination of BRAF- and MEK inhibition, anti-
PD-1 therapy or a combined blocking of PD-1 and CTLA-4 are recommended21. 
 
Altogether, activation of the host immune system has led to a variety of new therapy 
options, especially for metastatic melanoma patients. As a result, the therapeutic 
landscape of melanoma is becoming more and more complex, creating the need for 
markers that provide a support for decisions between different clinical strategies on 
an individualized basis. 
 
3.2 The tumor microenvironment 
As mentioned previously, the interaction between cancer cells and their 
microenvironment plays a major role in melanoma progression and metastasis11, and 
might therefore be a promising source of new biomarkers. The microenvironment is 
defined as the cellular and non-cellular components of the tumor niche34. The cellular 
components include fibroblasts and immune cells (such as T cells, B cells, 
monocytes/macrophages, NK cells, neutrophils, dendritic cells and tissue-specific 
immune cells), but also endothelial cells, pericytes and adipocytes. The non-cellular 
components include extracellular matrix (ECM) components and secreted 
molecules44. 
 
Figure 1: Simplified scheme of the tumor microenvironment. This represents a simplified overview without 
any claim to completeness. ECM=Extracellular matrix. NK cells=natural killer cells. 
Fibroblasts represent the most abundant cell type in the microenvironment of many 
tumors, besides the tumor cells themselves45. These cancer-associated fibroblasts 
(CAFs) are currently the subject of research in many different tumors, including 
melanoma46. Monocytes/macrophages represent an important first line of defense 




the malignant cells, tumor-associated macrophages (TAMs) play a key role in 
melanoma progression48. Therefore, these two stromal cell types will be described in 
more detail in the next sections. 
3.2.1 Cancer-associated fibroblasts 
Fibroblasts are spindle-shaped cells of mesenchymal origin that do not express 
epithelial (cytokeratin, E-cadherin), endothelial (CD31) or immune (CD45) cell 
markers49. Physiologically, they are involved in homeostasis of the ECM by secreting, 
modifying and degrading its components50. Through the production of basement 
membrane components, fibroblasts control the polarity of epithelial cells51. From their 
quiescent state, they are able to become activated in response to growth stimuli. 
Then, they proliferate, migrate, change their cytoskeleton architecture to be more 
contractile, and secrete cytokines, chemokines and ECM components49. Hence, 
fibroblasts are also key players in wound healing, acute and chronic inflammation, 
fibrosis, cancer and many other processes50. 
 
As a result of their interaction with malignant cells, fibroblasts can become CAFs, but 
their phenotype varies in different malignancies52. In many tumors including 
melanoma, the main source of CAFs are resident fibroblasts that become stimulated 
through tumor-derived transforming growth factor beta 1 (TGFβ1)46. In addition, bone 
marrow-derived mesenchymal stem cells, adipocytes, epithelial, endothelial or 
smooth muscle cells, pericytes or fibrocytes can also give rise to CAFs53. 
 
Due to their heterogeneity, CAFs cannot be defined by a single marker, but are 
characterized by a set of potential markers. For instance, alpha-smooth muscle actin 
(α-SMA), a TGFβ1-inducible isoform of the cytoskeleton protein actin, is 
characteristic of CAF populations in melanoma and various other tumors54. It is 
involved in the wound healing-associated formation of stress fibers and is closely 
linked to myofibroblast differentiation55. Additionally, fibroblast activation protein 
(FAP), fibroblast-specific protein 1 (FSP1, also known as S100 calcium-binding 
protein A4) and platelet-derived growth factor receptors α and β (PDGFRα and β) 
can identify CAFs, depending on the tumor56. 
 
CAFs can foster melanoma progression through various mechanisms. For instance, 
the direct interaction between CAFs and melanoma cells mediated through CAF 
surface-bound CD44 promoted melanoma growth and maintained the stemness of 
tumor-initiating cells57. Direct binding of melanoma cells to N-cadherin expressed by 
dermal CAFs facilitated melanoma invasion through the basal membrane and 
activated antiapoptotic pathways in melanoma cells58. Additionally, factors secreted 
by CAFs such as interleukin (IL) 6 and 8 were found to promote melanoma 
invasiveness59.  
A major role of CAFs is the remodeling of the ECM through the production of TGFβ1, 
matrix components and proteolytic enzymes such as matrix-metalloproteases 




including melanoma63. Matrix remodeling by CAFs can be mediated through TGFβ1, 
and was observed to enhance melanoma growth and metastasis in vivo64. Others 
found that MMP263 and MMP1365 produced by CAFs stimulated melanoma growth. 
CAF-derived MMP2 can also cleave activating ligands from the cell surface of NK 
cells, thereby suppressing their antitumor cytotoxicity66. Furthermore, by remodeling 
the ECM, melanoma-associated fibroblasts exposed to BRAFi can cause increased 
adhesion of melanoma cells to the ECM via integrin β-1, leading to intracellular 
activation of focal adhesion kinase (FAK). FAK activity results in MAPK-independent 
activation of the downstream extracellular signal regulated kinase (ERK), and thus 
BRAFi resistance67. MMP9 secreted by CAFs can cleave PD-L1 from the surface of 
melanoma cells, leading to anti-PD-1 therapy resistance. Consistent with the 
importance of TGFβ1 in CAF function, this study also showed that established 
therapy resistance to anti-PD-1 therapy could be mitigated by TGFβ1 inhibition68.  
 
In tumors other than melanoma, the histological presence of CAFs has been 
associated with poor outcome, for example in oral squamous cell carcinoma 
(OSCC)69, colorectal carcinoma70 and breast cancer71. Recently, an association 
between the local expression of connective tissue growth factor by CAFs and poor 
disease-free survival in a small cohort of 46 melanoma patients nearly reached 
significance (logrank test: p=0.06)72, suggesting that molecules produced by CAFs in 
melanoma might have a prognostic potential. 
 
In summary, it is clear that CAFs and the factors they produce can contribute to 
tumor progression, but an association with patient outcome has not yet been 
investigated sufficiently in melanoma.  
3.2.2 Tumor-associated macrophages 
Monocytes are recruited from the blood to several tissues and can be differentiated 
into distinct types of macrophages. In general, macrophages are responsible for 
antigen-presentation, as well as recognition and phagocytic elimination of foreign 
material and apoptotic cells. They play an important role in tissue repair and wound 
healing as well as inflammatory responses47. 
 
Due to the plasticity and complexity of macrophage phenotypes, different 
classification systems with respect to markers, function and polarizing agents of 
human and murine macrophage subtypes can be found in the literature. Most 
classification systems for macrophages include at least two activated phenotypes: 
classically activated M1 macrophages, and alternatively activated M2 macrophages. 
Generally, M1 and M2 macrophage subtypes are considered to represent the 
extremes of a continuum. A switch from M1 to M2 or vice-versa might be possible73. 
 
Polarization of macrophages into the M1 phenotype can be conditioned through IFN-
γ, bacterial lipopolysaccharides or toll-like receptor (TLR) agonists. The M1 




functions, and is characterized by high levels of major histocompatibility complex 
class II molecules (MHCII), IL1 and IL12, and low levels of IL1073-75. M2 
macrophages on the other hand promote immune suppression, and display low 
levels of IL12 and MHCII and high levels of IL10.  
Different subtypes of M2 macrophages have been described, whose generation 
depends on the stimulus to which they have been exposed. IL4 or IL13 stimulation 
gives rise to “alternatively activated” M2a macrophages, which are responsible for 
allergic responses and the elimination of parasites and fungi. The M2b phenotype, 
also referred to as “type 2 macrophage”, is activated by immune complexes and TLR 
ligands, and negatively regulates other immune cells. Alternatively, glucocorticoids, 
IL10 or TGFβ1 can polarize monocytes towards “deactivated” M2c macrophages, 
which regulate immune responses as well as ECM remodeling73, 75, 76. 
 
TAMs represent a third phenotype that monocytes can adopt when exposed to 
tumor-derived factors77. The main sources of TAMs are monocytes from peripheral 
blood vessels78. Through cancer-derived factors, they are recruited to the primary 
tumor, where they then further differentiate. These factors depend on the cancer 
type, and not all conditions that lead to TAM recruitment and polarization have been 
elucidated yet. In melanoma, it has been reported that tumor-derived CC-chemokine 
ligand (CCL) 2, vascular endothelial growth factor (VEGF) C48, VEGFA, IL34, CXC 
chemokine ligand (CXCL) 1279 and macrophage colony-stimulating factor (M-CSF)80 
might play a role in the generation of TAMs. 
TAMs are believed to resemble M2 macrophages81, and they are sometimes referred 
to as “M2d macrophages”75. However, other evidence suggests that TAMs can share 
properties of M1 and M2 macrophages77. The surface-bound receptor CD163 is 
commonly used to identify TAMs in situ in several types of cancer77, including 
melanoma82, 83, but it seems to be expressed by certain subsets of M2 
macrophages84. The following Figure 2 summarizes the most important features and 





Figure 2: Simplified overview of human macrophage phenotypes (based on references73-77, 84). The red 
color indicates factors polarizing towards a certain phenotype. The molecules in a colored box are produced by 
the corresponding macrophage subtype (same color as the box). Both represent examples without any claim to 
completeness. CCL=C-C-chemokine ligand, CD=cluster of differentiation, IL=interleukin, IFN=interferon, 
LPS=lipopolysaccharide, MHC=major histocompatibility complex, MMP=matrix-metalloproteases, TAM=tumor-
associated macrophage, TGFβ=transforming growth factor beta, TLR=toll-like receptor, TNF=tumor necrosis 
factor. 
TAM infiltration is associated with poor prognosis and metastasis in various tumors 
including gastric cancer85, OSCC86, lung adenocarcinoma87, breast cancer88 and 
melanoma89. Once recruited, TAMs have been shown to promote melanoma 
progression in different ways. For example, they can foster melanoma growth 
through the production of IFN-γ90, IL1B and other factors48. TAMs also endowed 
melanoma cell lines in vitro with resistance to BRAFi, which was mediated by their 
secretion of MAPK pathway-activating growth factors91. Additionally, they increased 
the survival of cancer initiating cells in melanoma and promoted sphere formation 
through the TGFβ1- and arginase pathways92. 
In addition to direct effects on melanoma cells, TAMs can also shape a 
microenvironment that promotes melanoma growth. For example TAMs foster tumor 
angiogenesis by secreting VEGFs, fibroblast growth factor (FGF), PDGF isoforms 
and prostaglandin E2, which are known to act as proangiogenic factors73. TAMs also 
produce proteases, including cathepsin B, MMP2, 7 and 9, that cleave the ECM, and 
thereby facilitate angiogenesis and tumor cell invasion81. Furthermore, by secreting 
immunosuppressive molecules such as IL10 and TGFβ1, TAMs can blunt the 
antitumor response, since these factors recruit Tregs and dampen the function of 




molecules such as PD-L1, which further contributes to the suppression of antitumor 
immunity93. 
3.2.3 Crosstalk in the tumor microenvironment 
The development of a tumor-promoting microenvironment is a dynamic progressive 
process94. The interaction between specific stromal cells with tumor cells has been 
the focus of much research in recent years. This crosstalk is often mediated through 
the secretion of growth factors, cytokines and proteases. As outlined before, CAFs 
and the factors they produce as a result of their interaction with tumor cells can 
contribute to tumor progression, but correlation of these factors with patient 
prognosis has not been properly investigated in melanoma. The histological 
presence of TAMs themselves is associated with poor prognosis in melanoma89, but 
it remains unclear how TAMs might produce factors potentially linked to melanoma 
patient outcome.  
The increased expression of growth factors and cytokines involved in the crosstalk 
within the tumor microenvironment can result in higher levels of such factors being 
present in the blood of melanoma patients compared to healthy individuals. 
Transforming growth factor beta 1 (TGFβ1) and serum amyloid A (SAA) play an 
important role in the communications between stromal and tumor cells, and have 
been found at increased levels in the blood of melanoma patients95, 96. Therefore, a 
central aim of this thesis was to examine the transcriptional response of fibroblasts 
and monocytic cells to TGFβ1 and SAA, and to determine its prognostic significance. 
The role of TGFβ1 and SAA in physiology and cancer (with a focus on melanoma) 
will now be considered in the following two sections. 
 
3.3 Transforming growth factor beta 1 
TGFβ1 is a context-dependent cytokine involved in many physiological and 
pathological processes. In humans, there are three TGFβ isoforms. The main 
sources of TGFβ1 are platelets, immune cells including monocytes/macrophages, as 
well as fibroblasts and epithelial cells. TGFβ2 is physiologically produced by 
keratinocytes and glial cells, and TGFβ3 can be found in human kidney, liver and 
spleen and in embryonic heart and lung tissue97. 
 
TGFβ isoforms are secreted as inactive pre-pro-TGFβ, bound to latency-associated 
peptide (LAP). In this condition, they can be stored in intracellular granules, at the 
cell surface or in the ECM. There, the TGFβ-LAP complex binds to latent-TGFβ-
binding protein98. There are different mechanisms by which active TGFβ can be 
released from this complex. They include acidic conditions99, the presence of reactive 
oxygen species and ionizing radiation, proteolytic cleavage, and proteins that anchor 
the latent TGFβ-complex to ECM components or the active TGFβ molecule to cell 
membranes100. 
Upon release, TGFβ isoforms can bind to three different transmembrane receptors: 




facilitates the binding of TGFβ to the other receptors that are involved in intracellular 
signal transduction. The binding of TGFβ isoforms causes the formation of a hetero-
tetrameric complex of TGFBRI and II. Thereafter, the serine/threonine kinase domain 
of TGFBRII activates TGFBRI, which then initiates intracellular signaling100. This is 
dependent on the sma/mothers against decapentaplegic (Smad) proteins, including 
Smad2, 3 and 4. Smad2 and 3 are phosphorylated and form oligomeric structures 
with Smad4. Then, this complex is translocated into the nucleus, where the Smad 
proteins act as transcription factors. Simultaneously, Smad pathway activation leads 
to the upregulation of inhibitory Smads such as Smad7, which cause a negative 
feedback control of the pathway101. Besides the Smad-dependent signaling, TGFβ 
receptors can amongst others also activate the MAPK- or PI3K pathways100, 102. 
 
Altogether, these pathways regulate the transcription of genes involved in cellular 
proliferation, apoptosis, differentiation and migration103. Therefore, TGFβ plays an 
important role in injury repair, tissue fibrosis104, epithelial-mesenchymal transition 
(EMT)105, immune modulation, embryonic development and cancer106. 
3.3.1 TGFβ in melanoma and other tumors 
In tumors, TGFβ can be produced both by cancer cells, as well as by cells of the 
microenvironment including fibroblasts, macrophages and platelets107. Accordingly, 
increased systemic levels of TGFβ isoforms can be found in the blood of tumor 
patients and correlate with poor prognosis and metastasis in many tumors, including 
glioma108, colorectal carcinoma109, pancreatic ductal adenocarcinoma110, lung 
adenocarcinoma111 and melanoma95, 112.  
 
The roles of TGFβ in melanoma progression are highly context-dependent. In healthy 
skin and early melanomagenesis, TGFβ1 rather acts as a tumor suppressor. For 
instance, it upregulates cyclin-dependent kinase-inhibitors such as p21, which leads 
to cell cycle arrest in the G1 phase113. Additionally, TGFβ1 can induce apoptosis 
through different mechanisms114, and it can repress proliferative factors including the 
cellular/cancer-myelocytomatosis oncogene and the inhibitor of differentiation 
proteins115. Melanomas are known to develop resistance to these inhibitory effects of 
TGFβ1, for example through increased expression of repressors such as Smad7116. 
Malignant melanoma cells secrete more TGFβ1 than healthy cells, and also produce 
TGFβ2 and 3117. In melanoma, TGFβ isoforms additionally promote their own 
expression116. This leads to the death of surrounding nonmalignant melanocytes or 
tumor cells that have not yet developed resistance to the apoptotic effects of TGFβ97. 
TGFβ1 also stimulates proliferation118, as well as the acquisition of stem cell-like 
properties in melanoma cells100. 
TGFβ1 induces EMT in various cell types105 including melanoma cells119, and 
promotes melanoma migration and invasion119. In tumor and stromal cells, TGFβ1 
was found to mediate the secretion of collagen, fibronectin, and tenascin C and 




proangiogenic VEGFs and IL697 in various cell types, including epithelial cells and 
fibroblasts107. 
TGFβ1 can inhibit leukocyte proliferation, differentiation and survival102. Accordingly, 
TGFβ1 fosters tumor cell immune evasion by suppressing the cytotoxic gene 
program in T lymphocytes104 and inhibiting the activation of NK cells120. TGFβ1 also 
reduces the migration of antigen-presenting cells that recognize malignant cells into 
the tumor104. Furthermore, it promotes the recruitment and differentiation of 
immunosuppressive Tregs121, which is associated with melanoma progression122. 
Additionally, TGFβ1 contributes to the polarization of stromal cells towards tumor-
promoting phenotypes100, including TAMs123 and CAFs46. 
 
In summary, TGFβ1 plays an important role in melanoma progression and in the 
communication between tumor and stromal cells. 
 
3.4 Serum amyloid A 
The serum amyloid A proteins are a family of four homologous proteins. SAA1 and 2 
can be produced by the liver as a response to inflammatory stimuli and host injury124. 
The SAA3 gene is a pseudogene in humans125, and has similar functions in rodents 
as human SAA1 and 2126. SAA4 is constitutively present in the blood127, and will 
therefore not be considered here. As SAA1 and 2 proteins are structurally more than 
90% identical128, they will further be referred to as SAA. SAA plays an important role 
in diseases that have a significant inflammatory component, such as AA-amyloidosis, 
rheumatoid arthritis129, atherosclerosis, obesity and diabetes mellitus type 2124. 
Additionally, it binds to circulating high density lipoprotein130 and is involved in 
cholesterol metabolism129. Its role in cancer is described in detail in section 3.4.1.  
 
SAA can act through different receptors, which mediate its role in various processes. 
Most of the functions of SAA involve formyl-peptide receptor 2 (FPR2), TLR2 and 
TLR4124, but there are also other receptors for SAA131, including the receptor for 
advanced glycation end products that also binds S100 proteins132. 
FPR2 is a G protein-coupled receptor that was found at monocytes, neutrophils, 
other immune cells133 and synovial fibroblasts132. Upon binding of SAA, FPR2 
activates the nuclear factor “kappa-light-chain-enhancer” of activated B cells (NF-
κB)134. This induced M-CSF, IL8 and CCL2 in monocytes and/or neutrophils135. 
Therefore, SAA plays a role in chemotaxis of immune cells in an indirect way by 
inducing the above-mentioned promigratory molecules through FPR2. Additionally, 
SAA can also have direct chemotactic effects on immune cells through FPR2136. 
Besides, SAA participates in ECM remodeling via FPR2 through upregulation of 
MMP9 in monocytes137, as well as MMP2 and 3 in fibroblasts132. 
TLR2 and 4 are highly conserved pattern recognition receptors that are expressed in 
cells such as monocytes and macrophages, synovial and dermal fibroblasts, 
endothelial cells and chrondrocytes138, 139. Upon stimulation of TLR4, NF-κB can be 




induction of proinflammatory molecules. TLR4 can also signal through other 
pathways independently of MyD88140. TLR2 stimulation similarly leads to MyD88-
dependent NF-κB signaling, or can additionally involve MAPK activation141. Through 
TLR2 stimulation, SAA has been reported to upregulate various M2-markers in 
macrophages, including IL10, TGFβ1142, IL33 and tumor necrosis factor alpha 
(TNFα)135. Additionally, the expression of CCL2, IL1B and IL6 was enhanced in a 
TLR2/4-dependent manner in monocytic cells and fibroblasts by SAA135. This 
cytokine induction by SAA plays an important role in the pathogenesis of rheumatoid 
arthritis143 and atherosclerosis128, as well as in the progression of various tumors. 
3.4.1 SAA in cancer 
Besides the hepatic production in response to inflammation, SAA can also be 
produced by malignant cells including melanoma cells144 and CAFs145, 146. 
Furthermore, SAA expression was found in monocyte/macrophage cell lines147, as 
well as in TAMs of breast cancer148 and melanoma149. Additionally, SAA proteins are 
associated with enhanced metastatic risk and poor prognosis in tumors of the lung150, 
breast148, ovary151, uterus51 and esophagus152. Importantly, proteomic profiling has 
identified SAA as an early blood-borne marker for poor survival in melanoma 
patients96. 
 
Despite its association with poor survival, the mechanisms through which SAA 
worsens patient outcome and promotes metastasis remain poorly investigated. In a 
variety of cancer types including melanoma, SAA was found to limit the antitumor 
immune response in vivo. For instance, SAA fostered the expansion of myeloid-
derived suppressor cells via TLR2 signaling153. It induced IL1B and IL6 in monocytes, 
which promoted the recruitment of immunosuppressive Tregs154. SAA has also been 
reported to upregulate immunosuppressive M2 markers in macrophages142. 
Furthermore, it fosters tumor cell invasion by inducing expression of MMPs124, and by 
interacting with adhesion proteins, thereby modulating the affinity of tumor cells for 
the ECM, which is crucial for the initiation of cell migration132. Moreover, the Sleeman 
lab has previously shown that the metastasis-associated protein S100A4 triggers a 
potent inflammatory response in breast cancer, in part by stimulating SAA 
expression. SAA then amplifies its own expression, as well as that of other 
inflammatory factors. In addition, ectopic expression of SAA in tumor cells was found 
to initiate metastasis formation in a broad spectrum of organs, which was 
accompanied by a massive infiltration of immune cells155. 
 
Taken together, the current evidence suggests that SAA is part of an inflammatory 




3.5 Aim of this thesis 
Factors produced by tumor-associated stromal cells as a consequence of an 
intercellular crosstalk represent a promising, but yet under-investigated source of 
potential prognostic markers in melanoma.  
Expression of TGFβ1 and SAA is strongly increased during melanoma progression. 
Accordingly, their expression in primary melanoma lesions as well as in the blood of 
melanoma patients is associated with poor prognosis96, 112, 144. As outlined before, 
both proteins are substantially involved in the crosstalk between melanoma cells and 
stromal cells of the cancer microenvironment: TGFβ1 activates cancer-associated 
fibroblasts and plays an important role in proliferation, invasion and antitumor 
immune escape of melanoma cells. SAA is a key molecule in cytokine induction and 
chemotaxis of immune cells, especially monocytic cells, and plays a role in 
metastasis.  
 
Based on these observations, I addressed three major questions during my doctoral 
thesis work:  
 
1. In melanoma, do malignant cells, stromal cells (such as fibroblasts and 
macrophages), or both contribute to the increased expression of TGFβ1 and SAA? 
 
2. Do SAA and TGFβ1 stimulate the expression of cancer-relevant genes in 
fibroblasts or macrophages? 
 
3. Is there a correlation between patient prognosis and any of the cancer-relevant 
genes whose expression is induced by stimulation of fibroblasts or macrophages with 
SAA or TGFβ1?  
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4 MATERIAL AND METHODS 
4.1 Material 
4.1.1 Cell culture 
Table 1: Reagents used for cell culture 
Component Distributor 
0.05% Trypsin/EDTA (1x), phenol red Thermo Fisher Scientific, Schwerte, Germany 
Advanced DMEM/F12 Thermo Fisher Scientific, Schwerte, Germany 
Advanced RPMI 1640 Medium Thermo Fisher Scientific, Schwerte, Germany 
Aqua Ad Inject Miniplasco connect (sterile H2O) B. Braun Melsungen AG, Melsungen, Germany 
B-27 supplement Gibco, Invitrogen, Karlsruhe, Germany 
b-FGF Peprotech, Rocky Hill, CT, US 
DMEM Thermo Fisher Scientific, Schwerte, Germany 
DMSO Merck KGaA, Darmstadt, Germany 
EGF Sigma-Aldrich/ Merck, Darmstadt, Germany 
FCS Thermo Fisher Scientific, Schwerte, Germany 
Heparin Sigma-Aldrich/ Merck, Darmstadt, Germany 
L-Glutamin Gibco, Invitrogen, Karlsruhe, Germany 
P/S Thermo Fisher Scientific, Schwerte, Germany 
PBS Thermo Fisher Scientific, Schwerte, Germany 
RPMI 1640 Medium Thermo Fisher Scientific, Schwerte, Germany 
Trypan blue Merck KGaA, Darmstadt, Germany 
 
Table 2: Reagents used for cell stimulation 




CLI-095=TAK242 243984-11-4 Cayman, Ann Arbor, MI, USA 
Human recombinant Apo-
SAA (E. coli-derived) 
300-13 Peprotech, Rocky Hill, CT, USA 
Human recombinant TGFβ1 
(HEK293-derived) 
100-21 Peprotech, Rocky Hill, CT, USA 
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4.1.2 Nucleic acid analysis 
Table 3: Reagents used for nucleic acid analysis 
Component Distributor 
Biozym LE Agarose 
Biozym Scientific GmbH, Hessisch Oldendorf, 
Germany 
Chloroform:isoamyl alcohol (24:1) Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
DEPC Merck KGaA, Darmstadt, Germany 
DNAse I Thermo Fisher Scientific, Schwerte, Germany 
DNAse I buffer (10x) Thermo Fisher Scientific, Schwerte, Germany 
dNTPs Thermo Fisher Scientific, Schwerte, Germany 
DreamTaq green buffer (10x) Thermo Fisher Scientific, Schwerte, Germany 
DreamTaq polymerase (5 U/μL) Thermo Fisher Scientific, Schwerte, Germany 
EDTA 50 mM Thermo Fisher Scientific, Schwerte, Germany 
Ethanol Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Ethidiumbromide Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Gene ruler 1 kb plus DNA ladder Thermo Fisher Scientific, Schwerte, Germany 
Isopropanol Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Power SYBR Green qPCR Master Mix Thermo Fisher Scientific, Schwerte, Germany 
Random Hexamer Primer Thermo Fisher Scientific, Schwerte, Germany 
RevertAid H Minus Reverse Transcriptase  Thermo Fisher Scientific, Schwerte, Germany 
RevertAid H Minus Reverse Transcriptase 
Buffer 
Thermo Fisher Scientific, Schwerte, Germany 
RNAse Exitus spray AppliChem, Darmstadt, Germany 
TRIzol reagent Thermo Fisher Scientific, Schwerte, Germany 
 
Primers were purchased from Metabion International AG, Planegg, Germany, and 
were used at a concentration of 0.4 μM for polymerase chain reaction (PCR) and 
0.5 μM for quantitative real-time PCR (qPCR). 
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Table 4: Primer pair sequences and annealing temperatures for polymerase chain reaction (PCR) and 
quantitative real-time polymerase chain-reaction (qPCR) 
Primer name Sequence (5’ → 3’) 
Annealing 
temperature (°C) 
hu_ASMA=ACTA2 for1 TGGGTGACGAAGCACAGAGC 55 
hu_ASMA=ACTA2 rev1 CTTCAGGGGCAACACGAAGC 55 
hu_CCL2=MCP1 for GGGCTGAGACTAACCCAGAAACATCC 55 
hu_CCL2=MCP1 rev TGGGTTGTGGAGTGAGTGTTCAAGT 55 
hu_CCL4 for2 CCAAACCAAAAGAAGCAAGC 55 
hu_CCL4 rev2 ACAGTGGACCATCCCCATAG 55 
hu_CCL5=RANTES for AACCCAGCAGTCGTCTTTGT 55 
hu_CCL5=RANTES rev TTCAAGGACTCTCCATCCTAGC 55 
hu_CD163 for TTGCCAGCAGTTAAATGTG 55 
hu_CD163 rev AGGACAGTGTTTGGGACTGG 55 
hu_CDH2 for1 CGTCCACCTTGAAATCTGCT 55 
hu_CDH2 rev1 TTACAGCGCAGTCTTACCGA  55 
hu_COL1A1 for1 CACACGTCTCGGTCATGGTA 55 
hu_COL1A1 rev1 AAGAGGAAGGCCAAGTCGAG 55 
hu_CSF1 for ATGACAGACAGGTGGAACTGCCAG 55 
hu_CSF1 rev TCACACAACTTCAGTAGGTTCAGG 55 
hu_CTGF for CAGCATGGACGTTCGTCTG 55 
hu_CTGF rev CCAACCACGGTTTGGTCCTT 55 
hu_CXCL12=SDF1 for ATGAACGCCAAGGTCGTGGTC 55 
hu_CXCL12=SDF1 rev CTTGTTTAAAGCTTTCTCCAGGTACT 55 
hu_CXCR4 for GCATGACGGACAAGTACAGGCT 55 
hu_CXCR4 rev AAAGTACCAGTTTGCCACGGC 55 
hu_FAP for1 TCAGTGTGAGTGCTCTCATTGTAT 55 
hu_FAP rev1 GCTGTGCTTGCCTTATTGGT 55 
hu_FBN1 for AAACATGGGCCTGTCCTGTA 55 
hu_FBN1 rev TCAATGGAGGAAGGTGTGTG 55 
hu_FGF1 for GAAGCCCAAACTCCTCTACTGTAG 55 
hu_FGF1 rev TGTTGTAATGGTTCTCCTCCAGC 55 
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hu_FGF2 for CCTCTCTCTTCTGCTTGAAGTTG  55 
hu_FGF2 rev AGCGGCTGTACTGCAAAAAC  55 
hu_FPR2 for GGATTTGCACCCACTGCATTT 55 
hu_FPR2 rev ATCCAAGGTCCGAGATCAC 55 
hu_GAPDH_for qPCR CGACCACTTTGTCAAGCTCA 55 
hu_GAPDH_rev qPCR AGGGGTCTACATGGCAACTG 55 
hu_G-CSF for GCTGTGCCACCCCGAGG 55 
hu_G-CSF rev TGCAGGAGCCCCTGGTAGAGG 55 
hu_GM-CSF=CSF2 for GTCTCCTGAACCTGAGTAGAGACA 55 
hu_GM-CSF=CSF2 rev AAGGGGATGACAAGCAGAAAGTCC 55 
hu_IL10 for2 GCCTAACATGCTTCGAGATC 55 
hu_IL10 rev2 TGATGTCTGGGTCTTGGTTC 55 
hu_IL12A for CCTTGCACTTCTGAAGAGATTGA 55 
hu_IL12A rev ACAGGGCCATCATAAAAGAGGT 55 
hu_IL1A_for TGTATGTGACTGCCCAAGATGAAG 55 
hu_IL1A_rev AGAGGAGGTTGGTCTCACTACC 55 
hu_IL1B_for CCACAGACCTTCCAGGAGAATG 55 
hu_IL1B_rev GTGCAGTTCAGTGATCGTACAGG 55 
hu_IL6_for AGACAGCCACTCACCTCTTCAG 55 
hu_IL6_rev TTCTGCCAGTGCCTCTTTGCTG 55 
hu_IL8 for qPCR AAGAGAGCTCTGTCTGGACC 55 
hu_IL8 for TAQ TGGGTGCAGAGGGTTGTG 55 
hu_IL8 rev qPCR GATATTCTCTTGGCCCTTGG 55 
hu_IL8 rev TAQ CAGACTAGGGTTGCCAGATTTA 55 
hu_MMP13 for 2 AACATCCAAAAACGCCAGAC 55 
hu_MMP13 rev2 GGAAGTTCTGGCCAAAATGA 55 
hu_MMP2 for CCACTGCCTTCGATACAC 55 
hu_MMP2 rev GAGCCACTCTCTGGAATCTTAAA 55 
hu_MMP3 for CACTCACAGACCTGACTCGGTT 55 
hu_MMP3 rev AAGCAGGATCACAGTTGGCTGG 55 
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hu_MMP9 for 2 GCACTGCAGGATGTCATAGG 55 
hu_MMP9 rev 2 ACGACGTCTTCCAGTACCGA 55 
hu_PDGFA for CACACCTCCTCGCTGTAGTATTTA 55 
hu_PDGFA rev GTTATCGGTGTAAATGTCATCCAA 55 
hu_PDGFB for TCCCGAGGAGCTTTATGAGA 55 
hu_PDGFB rev ACTGCACGTTGCGGTTGT 55 
hu_PDGFRA for1 AGGTGGTTGACCTTCAATGG 55 
hu_PDGFRA rev 1 TTTGATTTCTTCCAGCATTGTG 55 
hu_PDGFRB for1 CAGGAGAGACAGCAACAGCA 55 
hu_PDGFRB rev1 AACTGTGCCCACACCAGAAG 55 
hu_PD-L1 for 3 ATTTGGAGGATGTGCCAGAG 55 
hu_PD-L1 rev 3 CCAGCACACTGCGAATCAACA 55 
hu_RPLP0 for AGACAATGTGGGCTCCAAGCAGAT 55 
hu_RPLP0 rev GCATCATGGTGTTCTTGCCCATCA 55 
hu_S100A4 for 2 CCGGATCCATGGCGTGCCCTCTGG 55 
hu_S100A4 rev 2 CGAAGCTTTCATTTCTTCCTGGGCTG 55 
hu_S100A8 for GAATTTCCATGCCGTCTACAGG 55 
hu_S100A8 rev CCACGCCCATCTTTATCACCAG 55 
hu_S100A9 for AAAAGGTCATAGAACACATCATGG 55 
hu_S100A9 rev GAAGCTCAGCTGCTTGTCTG 55 
hu_SAA for1 * GCCGATGTAATTGGCTTCTC  55 
hu_SAA rev1 * AGCCGAAGCTTCTTTTCGTT  55 
hu_Serpine1=PAI-1 for  GGCCATTACTACGACATCCTG 55 
hu_Serpine1=PAI-1 rev GGTCATGTTGCCTTTCCAGT 55 
hu_Smad7 for 2 CCTTAGCCGACTCTGCGAACTA 55 
hu_Smad7 rev 2 CCAGATAATTCGTTCCCCCTGT 55 
hu_TGFB1 for 2 TGAACCGGCCTTTCCTGCTTCTCATG 55 
hu_TGFB1 rev 2 GCGGAAGTCAATGTACAGCTGCCGC 55 
hu_TGFB2 for2 CTCCATTGCTGAGACGTCAA 55 
hu_TGFB2 rev2 CGACGAAGAGTACTACGCCA 55 
Material and Methods 
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hu_TGFB3 for 2 CTGGATTGTGGTTCCATGCA 55 
hu_TGFB3 rev2 TCCCCGAATGCCTCACAT 55 
hu_TGFBR II for 2 CAGTTGCTCATGCAGGATTT 60 
hu_TGFBR II rev 2 GCACGTTCAGAAGTCGGTTA 60 
hu_TGFBR III for 2 TCGGAGCACTCCTGACGGGG 60 
hu_TGFBR III rev 2 TGGGCTGCGCTGCTGTTCTC 60 
hu_TIMP-1 for GGGACACCAGAAGTCAACCA 55 
hu_TIMP-1 for GGCTTGGAACCCTTTATACATC 55 
hu_TLR2 for TTTCACTGCTTTCAACTGGTA 55 
hu_TLR2 rev TGGAGAGGCTGATGATGAC 55 
hu_TLR4 for CAGAGTTGCTTTCAATGGCATC 55 
hu_TLR4 rev AGACTGTAATCAAGAACCTGGAGG 55 
hu_TNFa for GGCTCCAGGCGGTGCTTGTTC 55 
hu_TNFa rev AGACGGCGATGCGGCTGATG 55 
hu_uPA for CGCCACACACTGCTTCATTG 55 
hu_uPA rev CCCCTTGCGTGTTGGAGTT 55 
*the SAA primer pair amplifies both SAA1 and SAA2. 
4.1.3 Protein analysis 
Table 5: Reagents used for protein analysis 
Component Distributor 
BSA (fraction V), biotin-free Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Dako fat pen Dako, Hamburg, Germany 
Eosin Merck KGaA, Darmstadt, Germany 
Glacial acetic acid Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
H2O2 30 % Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Hematoxylin Merck KGaA, Darmstadt, Germany 
Limonene mounting medium Abcam, Cambridge, UK 
Mayer’s hemalum solution Merck KGaA, Darmstadt, Germany 
NaCl Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Polysorbate 20 (Tween20) Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
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Rabbit serum Thermo Fisher Scientific, Schwerte, Germany 
Roti-Histol for Histology Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
StayGreen AP substrate Kit Abcam, Cambridge, UK 
Target Retrieval Solution Citrate pH 6.1 
Agilent Technologies Deutschland GmbH & Co. 
KG, Waldbronn, Germany 
Tris-HCl Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Vectastain Elite ABC AP Kit Vector laboratories, Burlingame, CA, US 
Vectastain Elite ABC HRP Kit Vector laboratories, Burlingame, CA, US 
Vector NovaRed HRP Substrate Kit Vector laboratories, Burlingame, CA, US 
4.1.4 Buffers 
Table 6: Composition of buffers 
Buffer Components 
TBS 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, pH 
adjusted to 7.5  
TAE (50x) 
50 mM EDTA, 2 M Tris-HCl, 1 M glacial acetic 
acid 
4.1.5 Antibodies  
Table 7: Antibodies used for immunohistochemistry 
Antibody 
(species) 









































R&D Systems GmbH, Wiesbaden-
Nordenstadt, Germany 
*the anti-SAA antibody detects both SAA1 and 2. 
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4.1.6 Enzyme-linked immunoassay (ELISA) Kits 
Table 8: Enzyme-linked immunoassay (ELISA) Kits 
Target protein Catalogue number Distributor 
Human active TGFβ1 BMS 249-4 Thermo Fisher Scientific, Schwerte, Germany 
Human total PAI-1 DTSE100 R&D Systems GmbH, Wiesbaden, Germany 
4.1.7 Consumables 
Table 9: Consumables 
Consumable Distributor 
8-Microstrip classic (200 μl PCR tubes) Biovendis Ltd., Mannheim, Germany 
Aluminium foil Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Autoclavable waste bags Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Carpex Mouth guard BSN medical, Hamburg, Germany 
Cell culture dishes: 6 cm and 10 cm SARSTEDT AG & Co, Nümbrecht, Germany 




, SARSTEDT AG & Co, Nümbrecht, Germany 
Centrifuge tubes: 15 ml, 50 ml Nerbe Plus, Winsen/Luhe, Germany 
Greiner Cellstar serological pipettes (5 ml, 10 ml 
and 25 ml) 
Greiner Bio-One, Kremsmünster, Austria 
Handystep (Multistep pipette) Merck KGaA, Darmstadt, Germany 
Microscope coverslips: 24 mm x 60 mm Langenbrinck, Emmendingen, Germany 
Nitril gloves S powder-free, non-sterile neoLab Migge GmbH, Heidelberg, Germany 
Optical seal film for qPCR plates Biozym, Hessisch Oldendorf, Germany 
Parafilm Bemis Company, Inc., Neenah, WI, USA 
Pipette Tips: 20 µl, 200 µl, 1000 µl with and 
without filters 
Nerbe plus, Winsen/Luhe, Germany 
Pipettes: 2 µl to 20 µl, 20 µl to 200 µl, 100 µl to 
1000 µl 
Gilson, Middleton, WI, USA 
Precision wipes tissue wipers Kimberly clark professional, Roswell, USA 
qPCR plate Biozym, Hessisch Oldendorf, Germany 
Seal Film BZO (Optical adhesive film) 
Biozym Scientific GmbH, Hessisch Oldendorf, 
Germany 
Sterile Filters for syringes Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
SuperFrost Ultra Plus microscope slides Langenbrinck, Emmendingen, Germany 
Syringes: 10 ml, 20 ml BD Biosciences, Heidelberg, Germany 
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Tips for multistep pipettes: 5 ml, 10 ml Eppendorf AG, Hamburg, Germany 
Transferpette S (Multichannel pipette): 30 µl to 
300 µl 
Brand GmbH& Co. KG Heidelberg, Germany 
Tubes: 1.5 ml, 2 ml Eppendorf AG, Hamburg, Germany 
4.1.8 Devices 
Table 10: Devices 
Device Distributor 
Calculator Soennecken, Overath, Germany 
Centrifuge Heraeus Multifuge 1S-R 
Heraeus Deutschland GmbH & Co. KG, Hanau, 
Germany 
Centrifuge Heraeus pico 17 Thermo Fisher Scientific, Schwerte, Germany 
Cooling centrifuge Heraeus Fresco 17  Thermo Fisher Scientific, Schwerte, Germany 
Gel electrophoresis cell Mini Protean Tetra Cell 
Bio-Rad Laboratories GmbH, Rüdigheim, 
Germany 
Hera cell 150i CO2 incubator Thermo Fisher Scientific, Schwerte, Germany 
Hera cell safety bench Thermo Fisher Scientific, Schwerte, Germany 
Magnetic stirrer Heidolph Instruments, Schwabach, Germany 
Microscope axiovert 40CFL Zeiss, Oberkochen, Germany 
Microscope Zeiss Imager Z1 with AxioCam HRc Zeiss, Oberkochen, Germany 
Microwave oven NN E245WB Panasonic, Kadoma, Japan 
Mini-centrifuge neoLab Migge GmbH, Heidelberg, Germany 
PCR cycler Flexcycler Twin-Block 48 Analytik Jena, Jena, Germany 
PCR cycler PTC200 MJ Research, St. Bruno, Canada 
pH Meter 766 Calimatic 
Knick Elektronische Messgeräte GmbH & Co. 
KG, Berlin Germany 
Pipette controller PIPETBOY acu 2 
INTEGRA Biosciences Deutschland GmbH, 
Biebertal, Germany 
Plate reader Multiskan Ascent 96/384 Thermo Fisher Scientific, Schwerte, Germany 
Power Supply EV 231 Peqlab Biotechnologie, Erlangen, Germany 
qPCR Machine Stratagene Mx3005P 
Agilent Technologies Deutschland GmbH & Co. 
KG, Waldbronn, Germany 
Rotary microtome SLEE CUT 4060 SLEE medical, Mainz, Germany 
Rotating mixer RM5 Ingenieurbüro CAT, M. Zipperer GmbH 
Shaker Rotamax 120 
Heidolph Instruments GmbH& Co. KG, 
Schwabach, Germany 
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Spectrophotometer NanoDrop 2000 NanoDrop Technologies, Wilmington, USA 
Steam cooker Multigourmet Braun, Kronberg im Taunus, Germany 
Thermomixer compact Eppendorf AG, Hamburg, Germany 
Timer Neo Lab, Heidelberg, Germany 
Tube Rotator SB2 Stuart Equipment, Staffordshire, UK 
Vacuum pump MD4CNT+AK+EK 
VACUUBRAND GMBH + CO KG, Wertheim, 
Germany 
Vortex Mixer VWR International GmbH, Darmstadt, Germany 
Waterbath B-480 for paraffin block slices Büchi, Flawil, Switzerland 
Waterbath WB22 for cell culture 
Memmert GmbH + Co. KG, Büchenbach, 
Germany 
4.1.9 Software  
Table 11: Software  
Software Distributor 
Adobe Creative Suite 4 
Adobe Systems Corporation, San José, CA, 
USA 
Elisaanalysis.com Elisakit.com 
Graph Pad Prism 7  GraphPad Software, Inc., la Jolla, CA, USA 
Microsoft Office 
Microsoft Germany GmbH, Schwabing, 
Germany 
AxioVision Rel. 4.8 
Carl Zeiss MicroImageing GmbH, Jena, 
Germany 
MxPro MX3005P (v4.10) qPCR Software 
Agilent Technologies Deutschland GmbH & Co. 
KG, Waldbronn, Germany 
4.1.10 Patient-derived samples 
Formalin-fixed, paraffin-embedded tumor samples derived from patients with 
malignant melanoma at different stages were kindly provided by Prof. Dr. Utikal 
(Universitätsmedizin Mannheim/DKFZ cooperation unit dermatooncology). 
Human dermal fibroblasts GS3, GS4, GS5 and GGN77 were a gift from PD Dr. 
Herskind. They were derived from skin explants of post mastectomy patients as 
described previously156. 
Plasma samples of melanoma patients were a kind gift from Dr. Quagliata 
(Universitätsspital Basel/ Institut für Medizinische Genetik und Pathologie). The 
plasma was isolated from blood samples that were taken at the University of Zürich 
Hospital, funded by the University Research Priority Program. All patients have 
signed a patient release form, which has been approved by an ethics committee and 
assigned the numbers EK 647 and EK 800. 
  




4.2.1 Cell culture and stimulations 
The human melanoma cell lines A375, G361, Mewo and SKMel23 were a kind gift 
from Prof. Dr. Utikal, originally bought from the American Type Culture Collection 
(ATCC). The human melanoma cell lines CRL1, C32, HT144 and SKMel28 were 
purchased from ATCC. The human monocytic macrophage cell line THP-1 was 
kindly provided by Prof. Dr. Kzhyshkovska, purchased from ATCC, and was used as 
a model for naïve monocytic macrophages in the primary melanoma niche. The 
human melanoma cell lines as well as the THP-1 cells were used for a maximum of 
24 passages in total. Heat-inactivated fetal calf serum (FCS) was used for the culture 
of THP-1 cells in order to inactivate complement factors contained in FCS. Heat-
inactivation was performed in a pre-heated water bath at 56 °C for 30 min. Patient-
derived primary human dermal fibroblast (HDF) lines GS3, GS4, GS5 and GGN77 
were used as a model for naïve fibroblasts in the primary melanoma niche. They 
were used for a maximum of four passages. 
An overview of the cell’s origins and cell culture maintenance media is given in the 
following Table 12. Table 13 summarizes the media used during experiments. 
Melanoma cell lines as well as THP-1 cells were maintained at 37 °C, 5 % CO2, 
atmospheric oxygen and maximal humidity in a cell culture incubator. HDF were 
cultured at 7 % CO2 as previously described
156. 
 
Table 12: Characteristics and maintenance culture media of cell lines and primary cells 
Cell type Origin First description Maintenance culture medium 
A375 
(adherent) 
Primary tumor Giard et al.
157
 DMEM + 10 % FCS + 1 % P/S 
C32 
(adherent) 
Primary tumor  Chen et al.
158
















RPMI 1640 + 10 % FCS + 1 % P/S 




















 DMEM + 10 % FCS + 1 % P/S 
SKMel 23 
(adherent) 
Primary tumor Fogh et al.
161
 DMEM + 10 % FCS + 1 % P/S 
SKMel28 
(adherent) 
Primary tumor Fogh et al.
161










RPMI 1640 + 10 % heat-inactivated 
FCS + 1 % P/S 
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Table 13: Media during experiments for different cells 
Media during experiments Components 
HDF serum starvation medium Advanced DMEM/F12 + 1 % P/S 
THP-1 serum starvation medium RPMI 1640 + 1 % P/S 
Melanoma cell serum starvation medium: 
Melanosphere assay medium (MAM) 
Advanced RPMI or advanced DMEM/F12 
+ 2 % B27 + EGF (20 ng/ml) + b-FGF (20 ng/ml) 
+ Heparin (4 μg/ml)+ 1 % L-Glutamine + 1 % 
P/S 
 
For freezing, cells were centrifuged at 300 g for 3 to 5 min and re-suspended in a 
mixture of 90 % FCS and 10 % dimethyl sulfoxide (DMSO), then placed in 
isopropanol boxes at -80 °C. Thawing was performed by leaving the vial for 1 to 
2 min in a water bath at 37 °C and then carefully re-suspending the cells in pre-
warmed culture medium. All cells except HDF were then again centrifuged at 300 g 
for 3 to 5 min and re-suspended in fresh pre-warmed medium before their placement 
into the desired cell culture dish or flask. 
 
Human recombinant TGFβ1 (HEK293-derived) and SAA (E.coli-derived) were 
reconstituted according to the manufacturer’s recommendations as follows. TGFβ1 
was reconstituted in 1 % bovine serum albumin (BSA) with 10 mM citric acid in sterile 
distilled water (dH2O) to ensure the activation of latent TGFβ1
99. SAA was 
reconstituted in 1 % BSA in dH2O. The endotoxin levels of recombinant SAA were 
lower than 0.1 ng/µg, according to the manufacturer and as confirmed by others163. 
The TLR4 inhibitor CLI-095 (=TAK242) was reconstituted in DMSO according to the 
manufacturer’s protocol to a concentration of 2.5 µM. 
For TGFβ1 and SAA stimulation, a pilot concentration titration was performed to 
determine the optimal concentration for induction of a set of marker genes. An 
overview of stimulation conditions resulting from these preliminary tests is given in 
Table 14. 
 
Table 14: Concentrations of reagents used for stimulation 
Reagent HDF THP-1 cells 
CLI-095=TAK242  
5 µM 








24 h or 48 h 
10 ng/ml 
24 h or 48 h 
 
Expression of Smad7 was used as a response gene to monitor TGFβ1 stimulation of 
HDF and THP-1 cells101. For SAA-stimulated THP-1 cells, CCL2164 was used as 
response gene. Response markers for SAA-stimulated HDF were IL6165 and SAA166. 
Furthermore, for stimulated THP-1 cells, CD163 expression was tested as marker for 
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TAMs77. IL10 and IL12 expression was used to investigate M2/ M1 activation 
respectively76. Similarly, stimulated HDF were tested for α-SMA (ACTA2) expression 
as a marker for CAFs54. An overview of the different response markers for each 
condition is presented in Table 15. Based on a preliminary screen by PCR for each 
individual stimulation and cell type, expression of further genes was then investigated 
by qPCR. 
In these preliminary experiments, SAA stimulation upregulated expression of the 
corresponding markers in THP-1 cells but not in HDF. Therefore, the TLR4 inhibitor 
CLI-095 was exclusively used in SAA-stimulated THP-1 cells in order to test an 
involvement of TLR4 in the SAA-stimulated transcriptional response.  
 
Table 15: Response and activation markers for different cell types and different stimulations 
Stimulated cells Response marker(s) Activation marker(s) 
TGFβ1-stimulated THP-1 Smad 7
101
 





TGFβ1-stimulated HDF Smad 7
101
 







For messenger ribonucleic acid (mRNA) expression analysis and cell culture media 
isolation, THP-1 cells were seeded in serum-free Roswell Park Memorial Institute 
(RPMI) 1640 medium at a density of 400 000 cells/ml in a 12 well format in 1 ml of 
serum starvation medium. They were left to rest for 24 h before the stimulation with 
SAA or TGFβ1. After 24 h, supernatant and cells were harvested. 
For mRNA preparation, HDF were seeded in their usual culture medium mentioned 
above (150 000 cells in a 6 well format or 65 000 cells in a 12 well format). To 
harvest cell culture medium, 800 000 HDF were seeded in a 10 cm dish. In both 
assays, a medium change to serum-free advanced Dulbecco’s modified eagle 
medium (DMEM)/F12 was performed 24 h later, and again 24 h later. The cells were 
stimulated as indicated in Table 14. 
For the generation of melanoma cell conditioned medium and mRNA, 450 000 
melanoma cells were seeded into a T75 cell culture flask in their normal culture 
medium mentioned above. After washing with phosphate-buffered saline (PBS), a 
medium change to melanosphere assay medium (MAM) with a total volume of 8 ml 
was performed 24 h later. After an additional 72 h, supernatant and mRNA were 
harvested. 
The media during experiments in Table 13 were chosen out of a preliminary test with 
different cell culture media. The aim was to use a medium without FCS, containing 
relatively low levels of TGFβ1, and resulting in normal cell morphology and growth. 
Cell-free conditioned media were obtained by centrifuging the harvested conditioned 
medium at 18 000 g for 3 min, and then taking the liquid phase. Supernatants were 
frozen at -80 °C. 
Material and Methods 
32 
 
4.2.2 Nucleic acid analysis 
4.2.2.1 Ribonucleic acid isolation 
For Ribonucleic acid (RNA) isolation, the TRIzol reagent phase separation method 
was used. For 12 wells and smaller formats, cells were re-suspended in 0.5 ml of 
TRIzol reagent; for 6 wells or larger formats, 1 ml of TRIzol reagent was used. All 
following volumes take reference to 1 ml of TRIzol reagent. THP-1 cells in 
suspension were centrifuged at 300 g for 5 min, supernatant was transferred into a 
fresh tube and the remaining cells were re-suspended in TRIzol and pooled with the 
adherent THP-1 cell population on the cell culture plate. Before adding 200 µl of 
chloroform:isoamyl alcohol (24:1) per 1 ml of TRIzol, the cell-TRIzol-suspension was 
incubated for 5 min at room temperature. Then, the mixture was vortexed for 15 s 
and again incubated for 3 min at room temperature. Afterwards, the vials were 
centrifuged at 4 °C and 16 000 g for 15 min. Then, three phases were visible. The 
upper aqueous phase was pipetted into a fresh tube containing 500 µl of isopropanol. 
After mixing by multiple inversions, RNA was precipitated for 10 min at room 
temperature. Then, samples were centrifuged for 20 min at 16 000 g and 4 °C. 
Afterwards, a white RNA pellet was visible at the bottom of the tube. This was 
washed twice with 750 µl of 75 % ethanol by centrifuging at 7 500 g and 4 °C for 
5 min. After decanting the ethanol, the RNA pellet was air-dried and then dissolved in 
20 μl of diethylpyrocarbonate (DEPC)-treated H2O using a pre-heated thermoblock at 
55 °C for 10 min. Total RNA concentration was measured with a NanoDrop 
spectrophotometer. To remove any genomic DNA potentially carried over the RNA 
samples, 2 μg of RNA was treated with deoxyribonuclease (DNase) I for 30 min at 
37 °C using the PCR Cycler PTC200 or Flexcycler Twin-Block 48. 
 
Table 16: Deoxyribonucelase (DNAse) I digestion ingredients 
Ingredient Volume per reaction (µl) 
10 x DNase buffer 4 
DEPC-treated H2O 3 
DNase I 4 
 
The reaction was stopped by adding 3 µl of ethylenediaminetetraacetic acid (EDTA) 
to each well and then heating the samples to 65 °C for 10 min. 
4.2.2.2 Reverse transcription 
For complementary deoxyribonucleic acid (cDNA) synthesis, 1 μl of random primer 
was added to the DNase I-treated RNA and incubated at 65 °C for 5 min. Samples 
were cooled on ice. They were split into a reverse transcriptase-positive (RT+) and 
negative (RT-) sample. Reverse transcriptase (RT) was added to the RT+ sample to 
transcribe RNA into cDNA, and DEPC-treated H2O was added to the RT- sample 
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respectively. RT buffer as well as deoxyribonucleotide triphosphates (dNTPs) were 
added to both samples. Table 17 summarizes the ingredients for reverse 
transcription: 
 
Table 17: Reverse transcription (RT) ingredients 
Ingredient Volume per reaction (µl) 
10x RT buffer 5 
dNTPs 2 
Reverse transcriptase (RT+) or 
DEPC-treated H2O (RT-) 
1 
 
The reverse transcription was performed through the following incubation steps, 
using the PCR Cycler PTC200 or Flexcycler Twin-Block 48: 
 
Table 18: Reverse transcription (RT) program 
Step Temperature Time 
Annealing of random primers 25 °C 10 min 
Reverse transcription 42 °C 60 min 
Inactivation 72 °C 10 min 
Cooling 4 °C Hold 
 
Subsequently, the obtained cDNA was diluted 1:20 in DEPC-treated H2O. 
4.2.2.3 Polymerase chain reaction and quantitative real-time polymerase chain 
reaction 
PCR analysis of the RT+ and RT- samples was performed to analyze efficient 
removal of genomic DNA and afterwards to test primer specificity. To investigate 
transcriptional changes introduced by SAA- or TGFβ1 stimulation, a first screen of 
potential target genes was performed by PCR. Amplification of cDNA was performed 
using the PCR Cycler PTC200 or Flexcycler Twin-Block 48. The housekeeping gene 
in this case for melanoma cells and human fibroblasts was the 60S acidic ribosomal 
protein P0 (RPLP0), and for THP-1 cells glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) respectively. The mastermix for PCR is described in the 
following table: 
 
Table 19: Polymerase chain reaction (PCR) mastermix 
Ingredient Volume per reaction (µl) 
10x DreamTaq buffer 2.5 
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DEPC-treated H2O 14.8 
dNTPs 0.5 
DreamTaq 0.2 
Forward/reverse primer mix 2 
cDNA sample 5 
 
For PCR analysis, the following thermal profile was used. Steps 2) to 4) are the 
amplification steps and were repeated 32 to 40 times: 
 
Table 20: Polymerase chain reaction (PCR) program 
Step Temperature Time 
1) Initialization 95 °C 3 min 
2) Denaturation of double stranded 
DNA 
95 °C 30 s 
3) Primer annealing 55 °C or 60 °C * 45 s 
4) Elongation by DreamTaq 72 °C 10 s 
5) Cooling 4 °C Hold 
*annealing temperature depending on the primer: see Table 4 
 
The differentially regulated genes in this preliminary screen were then determined 
quantitatively by qPCR using a Stratagene Mx3005P device. This was performed 
with SYBR Green dye for detection. The mastermix for qPCR is described in the 
following table:  
 
Table 21: Quantitative real-time PCR (qPCR) ingredients 
Ingredient Volume per reaction (μl) 
DEPC-treated H2O 3 
Forward and reverse primer mix 2 
cDNA sample 5 
Power SYBR Green PCR Master Mix 10 
 
For qPCR analysis, the following thermal profile was used. Steps 2) to 4) are the 
amplification steps and were repeated 40 times. 
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Table 22: Quantitative real-time PCR (qPCR) program 
Step Temperature Time 
1) Initialization 95 °C 10 min 
2) Denaturation of double stranded 
DNA 
95 °C 30 s 
3) Primer annealing 55 °C or 60 °C * 1 min 
4) Elongation 72 °C 1 min 
5) Cooling 4 °C Hold 
*annealing temperature depending on the primer, see Table 4 
4.2.2.4 Analysis of qPCR data 
For expression analysis, MxPro MX3005P (v4.10) qPCR Software was applied to set 
a threshold in the linear phase of the amplification curves resulting in Ct-values (i.e. 
the number of cycles, by which the amplification curve has crossed the threshold). 
The same threshold value has been applied for the housekeeping gene and the gene 
of interest if they were analyzed in different qPCRs. Ct-values obtained for a 
housekeeping gene were subtracted from the Ct-value of the target gene (ΔCt). 
 
ΔCt = Ct (target gene) – Ct (housekeeping gene) 
 
The housekeeping gene in the case of qPCR was RPLP0 for melanoma cells and 
human fibroblasts, and GAPDH for THP-1 cells. To compare the expression of 
TGFβ1, 2, 3, SAA and Plasminogen activator inhibitor 1 (PAI-1) between melanoma 
cell lines, HDF and THP-1 cells, RPLP0 was used as a housekeeping gene for all cell 
types. 
The ΔCt model assumes that each cycle results in a doubling of DNA. Relative 
expression of the target gene compared to the housekeeping gene is therefore 
calculated as follows: 
 
Relative expression of target gene = 2-ΔCt  
 
To compare the relative expressions of treated vs untreated samples, the arithmetic 
mean of the 2-ΔCt-values of the replicates of the unstimulated cells was calculated, 
and the 2-ΔCt-values of the treated cells were divided by this mean for normalization. 
The normalization of endogenous expression of TGFβ1, 2, 3, SAA and PAI-1 of each 
cell type to the cell line G361 was carried out in an analogous way. 
 
All data for the human melanoma cell lines and THP-1 cells were generated in three 
biological replicates. For human primary fibroblasts, four independent healthy donors 
represent the replicates. All results are expressed as mean + standard error of the 
mean (SEM). 
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4.2.3 Protein analysis 
4.2.3.1 Immunohistochemistry 
Single stainings with S100B (marker for malignant melanoma cells30), CD163 
(marker for tumor-associated macrophages167) and the three molecules of interest 
were established for human melanoma patient samples. The anti-TGFβ- and anti-
SAA antibodies recognize all TGFβ and SAA isoforms respectively, as specified in 
the datasheets. Costainings were also performed for S100B together with each of the 
three molecules of interests, and for PAI-1 with CD163. To this end, 5 μm sections 
were cut with a rotary microtome and placed on microscope slides. Tissue sections 
on slides were dried at 37 °C overnight. For deparaffinization, tissue sections were 
incubated three times for 5 min in Roti-Histol, then for 3 min in 100 %, 96 %, 80 % 
and 70 % ethanol and for 3 min in dH2O. Antigen retrieval was then performed by 
boiling the sections for 30 min in a steam cooker, using a citrate-based target 
retrieval solution. For horseradish peroxidase (HRP)-based detection, endogenous 
peroxidase activity was quenched with a 3 % hydrogen peroxide (H2O2) solution for 
5 min, followed by washing in tris-buffered saline (TBS) for 5 min. Blocking was 
performed with 1 % biotin-free BSA in TBS for 1 h before primary antibody 
application. For the anti-CD163 antibody, 10 % rabbit serum in 1 % BSA was used 
for blocking. All primary antibodies were incubated over night at 4 °C. The following 
Table 23 indicates the concentration for HRP-based and alkaline phosphatase (AP)-
based detection. 
 




Concentration for AP 
detection 
Anti-SAA 20 μg/ml  
Anti-PAI-1 10 μg/ml  15 μg/ml 
Anti-S100B  1:600 * 
Anti-CD163 10 μg/ml  
Anti-TGFβ1,2,3 (anti-TGFβ) 16 μg/ml  
*for the anti-S100B antibody, concentrations were not available from the provider 
 
After primary antibody incubation, slides were washed for 5 min with TBS. Next, 
biotinylated secondary antibodies were incubated for 30 min at room temperature. 
After washing with TBS, the HRP reagent was incubated for 30 min or the AP 
reagent was incubated for 45 min, respectively. After another wash step as indicated 
above, enzyme substrates were added. The reaction was stopped with dH2O for 
5 min. In these experiments, the NovaRed HRP substrate produced a red-brown 
staining. The color resulting from the enzymatic degradation of the StayGreen AP 
substrate was blue-green. The incubation times of secondary antibodies as well as of 
the enzyme substrates are represented in the following table.  
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Anti-mouse made in horse 
(BA-2001,Vector laboratories ) 
7.5 μg/ml 5 min  
Anti-PAI-1 
(goat) 
Anti-goat made in rabbit 
(BA-5000, Vector laboratories) 
7.5 μg/ml 5 min 20 min 
Anti-S100B 
(rabbit) 
Anti-rabbit made in goat 
(BA-1000, Vector laboratories) 
7.5 μg/ml  20 min 
Anti-CD163 
(mouse) 
Anti-mouse made in rabbit 
(EO413,Dako) 




Anti-mouse made in horse 
(BA-2001, Vector laboratories) 
7.5 μg/ml 8 min  
 
Costainings were performed using a sequential procedure, with the primary 
antibodies raised in different species. The counterstaining was omitted and a 
hematoxylin and eosin (H.E.) stained section of the patient was included into the 
analysis. The following table summarizes the corresponding antibody pairs, species 
and detection methods for costainings: 
 















































Sections were dehydrated (3 min incubation in 70 %, 80 %, 96 % and 100 % ethanol) 
and then incubated three times for 5 min in Roti-Histol. Finally, they were mounted 
with Limonene mounting medium and dried at room temperature before the analysis 
with the Axio Imager Z1 microscope.  
4.2.3.2 Enzyme-linked immunosorbent assays 
To assess the levels of active total PAI-1 and TGFβ1 in the blood of melanoma 
patients, plasma samples were analyzed via enzyme-linked immunosorbent assay 
(ELISA). Additionally, culture medium from melanoma cells, THP-1 cells and HDF 
was analyzed for PAI-1 using ELISAs. Additionally, the amount of PAI-1 in cell 
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culture conditioned medium was determined in stimulated and unstimulated THP-1 
cells and HDF by this ELISA. 
The following table shows the different dilutions for melanoma patient plasma as well 
as conditioned medium. Reagents were diluted with the recommended sample 
dilution reagent provided in every ELISA Kit. 
 
Table 26: Dilutions for biological material undergoing the different enzyme-linked immunosorbent assays 
(ELISAs) 
Sample ELISA target protein Dilution of samples 
Patient plasma TGFβ1 1:30 
Patient plasma PAI-1 1:10 
Conditioned medium from HDF PAI-1 1:30 
Conditioned medium from THP-1 cells PAI-1 none 
Conditioned medium from melanoma cell lines PAI-1 none 
 
ELISAs were carried out according to the respective manufacturer protocols. The 
optical density of each well was determined using the microplate reader Multiskan 
Ascent 96/384 set to 450 nm wavelength. Another measurement at 540 nm was 
carried out and then subtracted from the optical density measured at 450 nm. For the 
calculation of the concentrations, the free web software elisaanalysis.com 
(https://elisaanalysis.com/) was used, performing a four parameter logistic (4-PL) 
curve-fit. Then, the concentration was multiplied by the dilution factor. 
 
All measurements were carried out in two technical replicates. The ELISAs with HDF 
were carried out with four biological replicates. ELISAs with two biological replicates 
of TGFβ1-stimulated THP-1 cells were performed. The results show the means + 
standard errors of the mean in the indicated concentrations. 
4.2.4 Statistical analysis 
The number of technical replicates is indicated in the description of each 
experimental procedure. Statistical analysis was performed using the Graph Pad 
Prism software. All error bars refer to the standard error of the mean. For 
comparisons between stimulated and unstimulated HDF, the paired student’s t-test 
was used to match the corresponding conditions of each donor-derived fibroblast 
line. The unpaired t-test was used to compare unstimulated and TGFβ1-stimulated 
THP-1 cells. The one-way ANOVA was used to compare the three different 
stimulation conditions for SAA-stimulated THP-1 cells with Sidak’s post hoc tests for 
multiple comparisons, in the following manner: Unstimulated THP-1 cells were 
compared to SAA-stimulated cells, and THP-1 cells incubated with SAA alone were 
compared to THP-1 cells incubated with the TLR4 inhibitor CLI-095 and then treated 
with SAA. 
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For survival analysis of melanoma patients with different levels of PAI-1 protein 
expression, z-scores measured by reverse-phase protein array and clinical data of 
the TCGA skin melanoma cohort (TCGA Provisional) were downloaded from the cBio 
portal168, 169. This cohort includes 479 samples from 471 patients. Concerning the 
overall survival (OS) analysis, there were clinical data and PAI-1 protein expression 
data available for 348 patients. Concerning the progression-free survival (PFS) 
analysis, there were 308 patients for which both clinical data and PAI-1 protein 
expression data were available. Next, samples were sorted by z-scores and the 
cutoff between low and high PAI-1 protein expression was set at the upper tertile. To 
calculate the statistical difference between Kaplan-Meier survival curves, the logrank 
test was used. In all experiments, the level of significance was p<0.05 (using the 
abbreviations "*" or “#” for p<0.05, “**” or “##” for p<0.01 and “***” or “###” for 





5.1 Identification of cells that express TGFβ and SAA in melanoma 
To determine which cells express TGFβ and SAA in melanoma, I took two 
approaches. First, immunohistochemistry was used to analyze sections of human 
melanoma. Then, I examined the expression of SAA and TGFβ1 in cultured human 
melanoma cell lines, in human dermal fibroblasts (HDF), and in the human monocytic 
macrophage cell line THP-1. 
5.1.1 Immunohistochemistry 
To assess the expression of TGFβ and SAA in human melanoma, consecutive 
sections from a melanoma patient (Clark level III, local tumor stage pT3) were 
stained with antibodies against S100B, as well as with TGFβ and SAA antibodies 
alone, or in the indicated combinations as sequential costainings. In addition, staining 
with hematoxylin and eosin (H.E.) was performed. 
 
 
Figure 3: Localization of TGFβ and SAA in human melanoma. Immunohistochemical stainings for S100B 
(blue) and TGFβ (brown) or SAA (brown) respectively in human melanoma sections. H.E=hematoxylin and eosin 
staining. The scale bar represents 50 μm. 
TGFβ was strongly expressed in both S100B-positive melanoma cells as well as in 
S100B-negative cells. SAA was expressed in S100B-positive cells, and also in some 
S100B-negative stromal cells. In conclusion, TGFβ and SAA isoforms are expressed 
in primary tumor niches of human melanomas, especially by but not restricted to 
tumor cells. 
5.1.2 Expression of TGFβ and SAA in human melanoma cells, THP-1 cells and HDF  
In order to investigate the mRNA expression of the three TGFβ isoforms and SAA, 




cell line THP-1 were analyzed by qPCR in three biological replicates. In addition, four 
different donor-derived HDF were included in the analysis. Expression was 
normalized to the melanoma cell line G361, which showed a relatively low overall 
expression of these molecules. 
 
 
Figure 4: mRNA expression levels of TGFβ and SAA isoforms in different cell types. TGFβ isoforms (A) as 
well as SAA (B) are expressed in eight human melanoma cell lines (n=3) and also in unstimulated HDF (n=4) and 
THP-1 cells (n=3), represented at the x-axis. The ordinate represents the relative mRNA expression normalized to 
the melanoma cell line G361. The error bars indicate standard errors of the mean.  
The melanoma cell lines had different mRNA expression profiles for TGFβ1, 2 and 3. 
Altogether, TGFβ1 mRNA levels were higher in most of the melanoma cell lines 
compared to THP-1 cells, whereas HDF showed intermediate levels. Additionally, 
HDF expressed relatively high levels of TGFβ2 and 3. These results are consistent 
with the staining of the anti-TGFβ-antibody (which recognizes all three TGFβ 
isoforms) in S100B-negative stromal cells in Figure 3. Additionally, SAA mRNA was 
expressed in most melanoma cell lines, and in lower amounts in HDF and 
unstimulated THP-1 cells. 
 
In conclusion, most melanoma cell lines produced relatively high amounts of SAA 
and TGFβ1 in comparison to HDF or THP-1 cells. These data, together with the 
immunohistochemistry data, suggest that in this context, melanoma cells are the 
main source of SAA and TGFβ1. In the next experiments, I therefore set out to 
investigate whether SAA and TGFβ1 produced by melanoma cells induce expression 





5.2 SAA induces a protumorigenic mRNA expression signature in THP-1 cells 
To test the impact of SAA stimulation on the transcription of cancer-relevant genes in 
monocytes/macrophages, THP-1 cells were stimulated with 100 ng/ml SAA for 24 h. 
The expression of a panel of genes associated with tumor and/or stromal progression 
was tested by PCR. This panel is listed in Table 4 with reference to the cancer- 
relevance of these genes. On the basis of the PCR results, the most highly up- or 
downregulated genes were then also analyzed by qPCR. In the case of SAA-
stimulated THP-1 cells, the expression of CD163 (as a marker for TAMs77), IL10 and 
IL12A (as markers for macrophage polarization76) and CCL2 (as a positive control for 
SAA stimulation164) were also assessed by qPCR (also see Table 15). 
To investigate a potential involvement of TLR4 in mediating the effects of SAA, cells 
were also incubated in the presence or absence of 5 μM of the TLR4 inhibitor CLI-
095 starting 6 h prior to SAA stimulation. 
 
 
Figure 5: SAA upregulates various factors in a TLR4-dependent way in THP-1 cells. The ordinate displays 
the mRNA fold change relative to the levels of the unstimulated cells. The error bars indicate standard errors of 
the mean (n=3, except for CCL4: n=2). To compare the different stimulation conditions, a one-way ANOVA with 
Sidak’s post hoc tests for multiple comparisons was used. “*”, “**” and “***” indicate statistically significant 
differences between unstimulated and stimulated cells; “#”, “##” and “###” indicate statistically significant 
differences between cells incubated with SAA alone vs. SAA-treatment after pre-incubation with the TLR4 
inhibitor CLI-095 ("*" or “#” for 0.01<p<0.05, “**” or “##” for 0.001<p<0.01 and “***” or “###” for p<0.001). 
SAA was able to induce its own expression as well as the expression of CCL2, 
CCL5, IL1B, MMP9, PD-L1 and S100A9, which were TLR4-dependent. A TLR4-
independent upregulation of CD163, IL8 and Smad7 was also observed. As 






To investigate the impact of SAA stimulation on fibroblasts in the cancer 
microenvironment, the four donor-derived HDF were also stimulated with 100 ng/ml 
SAA for 24 h. Again, a preliminary screen including genes linked to CAFs and tumor 
progression by PCR was carried out (Table 4). Here, HDF did not significantly 
change mRNA expression of the analyzed genes upon SAA stimulation. Therefore, 
cells were not pre-incubated with CLI-095. 
For quantitative analysis of response and activation markers in SAA-stimulated HDF, 
transcription of the corresponding genes mentioned in Table 15 was determined by 
qPCR. Additionally, transcription of PAI-1 and TGFβ1 was tested, as their expression 
has been previously described in CAFs (PAI-1170, TGFβ161). 
 
 
Figure 6: SAA-stimulated HDF do not show significant changes in transcription of the analyzed genes. 
The ordinate indicates the mRNA fold change relative to the unstimulated control, error bars display standard 
errors of the mean (n=4). The paired t-test was used to compare the stimulated condition with the unstimulated for 
each HDF line. 
These results indicate that SAA did not induce changes in expression of the 






5.3 TGFβ1 induces expression of protumorigenic factors in THP-1 cells and HDF  
To analyze the transcriptional response of THP-1 cells to TGFβ1, the cells were 
incubated with 10 ng/ml TGFβ1 for 24 h. As before, the expression of a panel of 
genes linked to tumor progression and functions of TAMs were assessed by PCR 
(Table 4), out of which the most up-/downregulated genes were then also quantified 
by qPCR. In addition, expression of marker genes for TGFβ1 stimulation (Table 15) 




Figure 7: TGFβ1-stimulated THP-1 cells upregulate mRNA expression of different molecules. The ordinate 
represents the mRNA expression fold change relative to the unstimulated control. The error bars indicate 
standard errors of the mean and an unpaired t-test was used to compare the unstimulated vs. the TGFβ1-
stimulated condition (n=3). Statistically significant differences between stimulated and unstimulated cells (p<0.05) 
are indicated by “*”.  
TGFβ1-stimulated THP-1 cells expressed significantly more IL10 and MMP2 at the 
mRNA level. Additionally, they showed a strong trend towards upregulating IL1B, 
PAI-1, PD-L1, SAA and Smad7 mRNA expression after TGFβ1 stimulation. As 
explained in detail later, these factors play a role in melanoma progression and 
metastasis. In contrast to the case with SAA stimulation, exposure to TGFβ1 did not 





To investigate the response of HDF to TGFβ1, cells were stimulated with 2.5 ng/ml 
TGFβ1 for 24 h. Figure 8 represents the qPCR analysis of genes whose expression 
was found to be increased in a larger preliminary screen, which included genes 
involved in tumor progression and functional roles of CAFs (Table 4). Additionally, 
markers for TGFβ1-stimulated HDF mentioned in Table 15 are shown in Figure 8.  
 
 
Figure 8: HDF upregulate various factors upon stimulation with TGFβ1. The ordinate displays the relative 
mRNA fold changes of these genes normalized to the unstimulated control. The error bars indicate standard 
errors of the mean. A paired t-test was used to compare the stimulated vs. unstimulated HDF (n=4). Statistically 
significant differences between stimulated and unstimulated cells (p<0.05) are indicated by “*”. 
TGFβ1 significantly induced its own expression in HDF, as well as the CAF marker α-
SMA (ACTA2). Several other CAF markers (FAP, PGRFRα and β and S100A4) were 
assessed, but none of them was upregulated (data not shown), indicating that TGFβ1 
alone does not upregulate them in vitro. TGFβ1-stimulated HDF also expressed more 
Smad7, which was narrowly not significant (p=0.054). Additionally, IL6, PAI-1 and 
SAA were expressed at higher levels upon TGFβ1 stimulation. As explained later, 
these factors are associated with the protumorigenic CAF phenotype and play a role 




5.4 Local overexpression of PAI-1 correlates with poor prognosis in melanoma 
Stimulation of HDF and THP-1 cells by SAA and TGFβ1 resulted in significant 
upregulation of a number of cancer-relevant genes. Of these, PAI-1 was strongly 
upregulated at the mRNA level in both TGFβ1-stimulated HDF and THP-1 cells. PAI-
1, encoded by the gene SerpinE1, is a serine protease inhibitor that can be induced 
through TGFβ1 signaling171. Recently, PAI-1 has been associated with poor outcome 
in various tumors172. In breast cancer, it is already established as a marker for poor 
outcome, and high PAI-1 predicts the benefit from adjuvant chemotherapy in early, 
lymph node negative breast cancer173. Recent studies suggest a potential 
mechanistic involvement of PAI-1 in melanoma metastasis. For instance, in the B16 
mouse melanoma model, stromal cell-derived PAI-1 promoted both the size of 
subcutaneous tumors and the extent of metastases174, and stimulated macrophage 
infiltration175. In human melanoma, increased expression of PAI-1 has been observed 
in cutaneous metastases176. Therefore, I next asked whether PAI-1 might be 
associated with poor outcome of melanoma patients. 
 
To address this question, PAI-1 protein expression in tumor samples of the TCGA 
Skin Cutaneous Melanoma cohort was correlated with overall survival (OS) and 
progression-free survival (PFS). Clinical data and protein expression z-scores were 
obtained from the online portal cBio Portal of cancer genomics168, 169. For OS 
analysis, there were 348 samples for which clinical data and PAI-1 expression was 




Figure 9: Higher PAI-1 protein expression levels in tumor samples of the TCGA melanoma cohort 
correlate with worse overall survival (A) and worse progression-free survival (B). The Kaplan Meier curves 
were generated with data from primary melanomas of the TCGA Skin Cutaneous Melanoma cohort, retrieved 
from the cBioPortal of Cancer Genomics
168, 169
. The percentage of surviving patients is represented at the 
ordinate. Overall survival (A, n=348) or progression-free survival (B, n=308) are represented on the x-axis. The 
upper tertile was set as a cutoff between low and high PAI-1 protein levels. The logrank test was used to compare 
the patients with low PAI-1 levels (blue) to the patients with high levels (red). 
As shown in Figure 9, melanoma patients with higher PAI-1 protein levels in their 




levels (logrank test p<0.0001). Furthermore, the progression-free survival in those 
patients was also significantly shorter (logrank test p=0.0018). 
 
5.5 PAI-1 is produced by both melanoma and stromal cells 
TGFβ1 stimulation of HDF and THP-1 strongly upregulated PAI-1 expression (Figure 
7 and Figure 8), suggesting that CAFs and/or TAMs might be a source of PAI-1 in 
melanoma. Therefore, I carried out further experiments to investigate which cell types 
express PAI-1 in primary melanoma lesions. 
5.5.1 Immunohistochemistry 
To visualize the expression of PAI-1 in primary melanoma, costainings of PAI-1 
together with S100B were performed as described previously. Additionally, 
costainings with CD163 and PAI-1 were carried out. 
 
 
Figure 10: Expression of PAI-1 in human melanoma. Immunohistochemical stainings against S100B (blue) 
and PAI-1 (brown) as well as CD163 (brown) and PAI-1 (blue) in human primary melanoma. H.E.=hematoxylin-
eosin staining. The scaling bar represents 50 μm or 20 μm (inset).  
In these stainings, PAI-1 was present in S100B-positive melanoma cells, but also in 
the S100B-negative stroma. Certain stromal and tumor cells showed a stronger 
staining than others. Additionally, some CD163-positive stromal cells also expressed 
PAI-1. This suggests that melanoma cells and stromal cells including CD163-positive 





5.5.2 Some melanoma cell lines and unstimulated HDF produce PAI-1 
Next, I determined the levels of PAI-1 transcription and protein secretion in 
melanoma cells, macrophages and fibroblasts. Transcription of PAI-1 in human 
melanoma cell lines, THP-1 cells and HDF was therefore assessed by qPCR as 
previously described. Expression was normalized to the melanoma cell line G361. To 
determine the levels of secreted PAI-1, conditioned medium from the eight 




Figure 11: PAI-1 transcription (A) and protein secretion (B) in melanoma cell lines, unstimulated HDF and 
THP-1. (A) PAI-1 mRNA is expressed by eight human melanoma cell lines (n=3) and also by unstimulated HDF 
(n=4) and THP-1 cells (n=3). The ordinate represents the relative mRNA expression normalized to the melanoma 
cell line G361. (B) PAI-1 protein is secreted by some melanoma cell lines (n=1) and unstimulated HDF (n=4), but 
not by unstimulated THP-1 cells (n=1). The ordinate represents the amounts of PAI-1 measured by ELISA in 
ng/ml. Error bars refer to standard errors of the mean. PAI-1 protein levels of unstimulated HDF and THP-1 in this 
figure were from the same experiments as in Figure 12. N.d.=not detectable. 
HDF and some melanoma cell lines (Mewo, CRL1) produced high amounts of PAI-1, 
whereas the other melanoma cell lines showed low mRNA expression and protein 
secretion levels of PAI-1. The melanoma cell lines C32 and SKMel23 as well as 
unstimulated THP-1 cells produced undetectable amounts of PAI-1. The melanoma 
cell lines with lower levels of TGFβ1 (Figure 4, e.g. C32, G361, HT144, SKMel28), 
also expressed lower levels of PAI-1.  
 
In conclusion, these results show that certain melanoma cell lines as well as 





5.5.3 TGFβ1 stimulation induces PAI-1 secretion in THP-1 cells and HDF 
PAI-1 mRNA expression was upregulated in TGFβ1-stimulated HDF and THP-1 
(Figure 7 and Figure 8). To determine whether TGFβ1 also increases PAI-1 secretion 
in these cells, conditioned medium from THP-1 and HDF cells treated with and 
without TGFβ1 stimulation for 48 h was analyzed by ELISA. As shown in the 
following Figure 12, upon stimulation with TGFβ1, both HDF and THP-1 cells 
secreted significantly more PAI-1. 
 
 
Figure 12: PAI-1 protein levels secreted by THP-1 cells and HDF upon TGFβ1 stimulation. The ordinate 
represents the concentration of PAI-1 measured by ELISA in ng/ml (A) or pg/ml (B) respectively. The error bars 
indicate standard errors of the mean. A paired t-test was used to compare unstimulated and TGFβ1-stimulated 
HDF (n=4); an unpaired t-test was used in the case of THP-1 cells (n=2). Statistically significant differences 
between stimulated and unstimulated cells are indicated by “*” (0.01<p<0.05) and “***” (p<0.001) respectively. 
PAI-1 protein levels of unstimulated HDF and THP-1 in this Figure as well as in Figure 11 were from the same 
experiment. N.d.=not detectable. 
Taken together, these results suggest that CAFs are likely to be an important source 
of PAI-1 in melanoma. Non-stimulated fibroblasts already produced relatively high 
amounts of PAI-1 protein, which was enhanced through TGFβ1 stimulation (Figure 
11 and Figure 12). The concentrations of PAI-1 protein produced by unstimulated 
HDF (mean around 150 ng/ml) as well as TGFβ1-stimulated HDF (mean around 250 
ng/ml) exceed those detected in melanoma cell lines (highest production by the cell 
line Mewo: mean around 100 ng/ml). Consistently, some stromal cells in Figure 10 
showed a strong staining for PAI-1, supporting a participation of stromal cells in PAI-
1 production. 
Although THP-1 cells increased PAI-1 production after TGFβ1 stimulation, the 
absolute protein levels were relatively low compared to melanoma cell lines or HDF. 
The positive staining for PAI-1 in CD163-positive cells in Figure 10 supports the 





5.5.4 Systemic levels of TGFβ1 and PAI-1 in melanoma patients correlate with each 
other 
The above findings indicate that increased transcription of PAI-1 in melanoma 
samples is associated with poor prognosis, and that TGFβ1 plays an important role in 
upregulating PAI-1. This might lead to the hypothesis that there could be a 
correlation between TGFβ1 and PAI-1 protein levels in the blood of melanoma 
patients. To determine if this is the case, I analyzed the levels of TGFβ1 and PAI-1 
by ELISA in the plasma of 22 patients. As shown in Figure 13, the plasma levels of 
PAI-1 strongly correlated with those of TGFβ1 in melanoma patients. 
 
 
Figure 13: Plasma levels of TGFβ1 and PAI-1 in melanoma patients positively correlate with each other. 
The Pearson correlation coefficient r for the plasma levels of TGFβ1 and PAI-1 in melanoma was calculated 










Increased TGFβ1 and SAA expression is associated with melanoma progression and 
poor prognosis. The data presented in this thesis show that melanoma cells 
represent an important source of TGFβ1 and SAA. Furthermore, my results suggest 
that TGFβ1 and SAA are involved in the crosstalk between melanoma cells on one 
hand, and tumor-associated fibroblasts and macrophages on the other, because both 
proteins induced the transcription of a number of genes related to tumor progression 
in HDF and THP-1 cells. Of particular interest, TGFβ1 significantly enhanced PAI-1 
production in both HDF and THP-1 cells, a protein associated with tumor progression 
in other contexts. Consistently, the systemic levels of TGFβ1 and PAI-1 positively 
correlated with each other in melanoma patients. Fibroblasts expressed relatively 
high PAI-1 levels before stimulation, which was strongly increased after treatment 
with TGFβ1, suggesting an important role for these cells as a source for locally 
increased PAI-1 levels. Importantly, increased local PAI-1 levels were associated 
with poor prognosis in melanoma patients. These results will further be 
contextualized in the following sections. 
 
6.1 Expression of TGFβ1 and SAA in the primary melanoma niche 
My results show that TGFβ isoforms are expressed in different melanoma cell lines 
(Figure 4), which is in line with previous studies112. TGFβ isoforms were found not 
only in melanoma cells, but also in stromal cells (Figure 3 and Figure 4). This is in 
line with the finding that TGFβ can be produced by stromal cells in response to 
several stimuli100. 
In my experiments, relatively high mRNA levels of TGFβ2 and 3 were observed in 
naïve HDF (Figure 4). Others have reported that skin fibroblasts express “baseline 
levels” of TGFβ2177, which is not in accordance with these results. However, TGFβ2 
and 3 expression levels in naïve HDF have not yet been directly compared to levels 
in melanoma cells. 
Interestingly, TGFβ1 upregulated its own transcription in HDF (Figure 8), which is in 
line with previous findings178. A feedforward loop might therefore contribute to the 
positive TGFβ staining that is observed in the stroma in Figure 3. This was only 
observed in HDF, and not in THP-1 cells in my experiments, suggesting that the 
feedforward loop that amplifies TGFβ1 might be more pronounced in HDF. 
Nevertheless, TAMs in situ can still express TGFβ1 due to other stimuli in the tumor 
niche179. 
 
SAA was also expressed in melanoma and stromal cells in Figure 3 and Figure 4. 
This is consistent with reported SAA expression in other malignant tissues such as 
lung150, breast148 and esophageal152 tumors. SAA has also been detected in 
melanoma cells and adjacent TAMs149, as well as CAFs isolated from pancreatic146 




THP-1 cells (Figure 4), consistent with previous findings147. In THP-1 cells, SAA was 
also observed to upregulate its own mRNA expression, which is in line with self-
amplifying loops reported for SAA in different cell types124. However, expression 
levels of SAA in melanoma and stromal cells have not yet been compared directly. 
 
6.2 Responses of THP-1 cells and HDF to SAA and TGFβ1 
6.2.1 SAA stimulates THP-1 cells to express a variety of tumor-promoting factors 
In my experiments, the stimulation of THP-1 cells with SAA upregulated the 
expression of a number of cancer-relevant genes. This increased expression was 
mainly TLR4 dependent (Figure 5). These results suggest that SAA in the tumor 
milieu may stimulate monocytic macrophages to produce tumor-promoting factors. 
 
The elevated production of IL1B by SAA-stimulated THP-1 has also been observed 
by others180 and involved TLR2, 4 or FPR2135. In various tumors including melanoma, 
IL1B plays a role in invasion, proliferation and stimulation of adjacent cells to produce 
proangiogenic molecules including IL8 and VEGF181. Additionally, IL1B can promote 
the differentiation of Tregs, and can be considered as initiator of immunotolerance154. 
A recent study reported that macrophages produce IL1B upon stimulation with 
melanoma conditioned medium, initiating a crosstalk with fibroblasts, which 
contributed to BRAFi resistance in melanoma82. My experiments suggest that 
melanoma-derived SAA might play a role in this IL1B production by monocytic cells. 
Interestingly, I also observed that PD-L1 expression was upregulated in SAA-
stimulated THP-1 cells. PD-L1 can be detected in tumor cells as well as antigen-
presenting cells including macrophages, where it inhibits the antitumor response of 
cytotoxic T cells and NK cells42. Hence, melanoma-derived SAA might contribute to 
PD-L1 expression by TAMs in the primary tumor niche, thereby suppressing 
antitumor immunity. 
Consistent with my results, IL8 has previously been detected in SAA-stimulated 
monocytes and THP-1 cells, where it mediated chemotaxis together with SAA and 
CCL3136. IL8 can promote angiogenesis, tumor growth and metastasis in melanoma 
and other cancers182. Additionally, a recent study reported that high systemic levels 
of IL8 in melanoma patients could predict poor response to PD1/PD-L1 blockade183. 
Hence, monocytes exposed to melanoma-derived SAA might contribute to elevated 
levels of IL8. 
SAA treatment of THP-1 cells resulted in enhanced transcription of MMP9, which is 
consistent with previous findings in the context of lung adenocarcinoma150. Others 
have reported that SAA-induced MMP9 upregulation in THP-1 cells in vitro depends 
on FPR2-mediated NF-κB activation137. In my experiments, blockade of TLR4 
dampened, but did not completely inhibit SAA-induced MMP9 expression, suggesting 
that FPR2 and TLR4 might both be relevant. The protease MMP9 degrades ECM 
components184, including basal membrane collagen type IV185, which facilitates tumor 




metastasis, angiogenesis and poor prognosis in many different tumors186. In addition, 
MMP9 can activate many cytokines and growth factors by proteolysis, including IL1B, 
IL8 and TGFβ1184. Further research is required to understand the contribution of 
SAA-stimulated monocytic cells to MMP9-mediated protumorigenic effects in 
melanoma. 
Smad7, a TGFβ1-inducible protein that suppresses the TGFβ1 pathway101, was 
upregulated in SAA-stimulated THP-1 cells. Similar to SAA, Smad7 can promote NF-
κB activation and cytokine secretion in macrophages187. Therefore, it might be 
interesting to test whether a crosstalk exists between intracellular pathways that are 
stimulated through TGFβ1 and SAA in monocytic cells, and how this impacts 
melanoma progression. 
In my experiments, SAA upregulated S100A9 and its own expression in THP-1 cells 
in a TLR4-dependent manner. S100A9 is part of the family of S100 calcium-binding 
proteins, it can induce SAA proteins in various cell types188 and has been associated 
with metastatic behavior189. Previously, others have shown in mouse models that 
melanoma-derived S100A8/A9 can induce SAA3 in distant pre-metastatic lungs. In 
this study, SAA initiated a positive feed-forward loop of chemoattractant secretion. 
This recruited monocytic cells and tumor cells to pre-metastatic lesions and promoted 
lung metastasis through TLR4- and NF-κB-dependent signaling190. The observation 
that SAA can induce its own expression in monocytic cells has not yet been reported 
to my knowledge. Melanoma patients in early tumor stages were found to have 
elevated systemic levels of SAA, which correlated with poor prognosis96. Therefore, 
induction of S100A9 and its own expression by SAA in monocytic cells might be part 
of a metastasis-initiating feedforward loop that is reflected by elevated systemic 
levels of SAA. 
 
It is unclear where SAA-stimulated THP-1 cells fit into the M1/M2 paradigm. Classical 
M1 markers such as IL12A and M2 markers such as IL10191 were not induced 
through SAA in naïve THP-1 cells. Nevertheless, some M1-related factors such as 
IL1B and IL8192 were upregulated. The upregulated chemokines CCL2 and 5, known 
to recruit monocytic cells136, have been linked to proinflammatory M1 macrophages76 
but also to TAMs77. Additionally, the TAM marker CD163 was upregulated through 
SAA, and mRNA levels of TAM-associated MMP978 were also elevated. Previous 
studies have reported that SAA induced the expression of a variety of M2 
macrophage markers in THP-1142, which I did not observe in my experiments. Others 
found that THP-1 cells pretreated with M-CSF show a mixed M1/M2 gene expression 
signature upon SAA stimulation, which was characterized by the expression of IL1B, 
IL6, IL10 and CD163193. Unpolarized M0 and proinflammatory M1-subpopulations of 
TAMs were described to be present in in situ-melanomas to a similar extent as M2-
TAMs194, suggesting that both phenotypes may play a role in melanoma progression. 
 
A possible reason for the mixed M1/M2 marker profile after SAA treatment is that 
THP-1 cells represent a mixed population of cells in different conditions between 
monocyte and macrophage195. To induce macrophage differentiation and to maintain 




THP-1 can be pre-treated with phorbol-12-myristate-13-acetate (PMA) or M-CSF196. 
However, PMA activates several intracellular pathways including the protein kinase C 
pathway197, 198, leads to accumulation of intracellular NF-κB199 and induces the 
expression of several proto-oncogenes200. Additionally, PMA promotes M1-
differentiation of THP-1 cells197. Considering these limitations and since the aim was 
to investigate the response to a single molecule (SAA/TGFβ1), non-pretreated THP-1 
cells were used in this thesis.  
 
In conclusion, SAA alone did not polarize naïve THP-1 cells, but induced expression 
of TAM-associated factors that are implicated in melanoma invasion, matrix 
remodeling, angiogenesis, immune evasion and therapy resistance. 
6.2.2 HDF were not susceptible to SAA stimulation 
HDF did not significantly change the expression of the panel of tested genes in 
response to SAA treatment (Figure 6). Variance in gene expression was observed 
between different patient-derived samples. In previous studies, synovial fibroblasts 
stimulated with SAA were found to upregulate various inflammatory molecules, 
including IL6, CCL2 and CXCL1, 2, 3 and 8, in a TLR4-dependent manner143. 
Amnion fibroblasts upregulated IL1B, IL6 and cyclooxygenase 2 upon SAA 
treatment134, and dermal fibroblasts were found to produce more IL6 through 
TLR2165. The different experimental context or origins of these fibroblasts might 
explain their enhanced responsiveness to SAA compared to the HDFs used in my 
experiments. 
6.2.3 THP-1 cells produce protumorigenic factors upon TGFβ1 treatment, including 
PAI-1 
TGFβ1 significantly upregulated IL10 and MMP2 transcription in THP-1 cells (Figure 
7). IL10 is associated with the M2 phenotype74 and plays an important role in the 
immune evasion of melanoma together with TGFβ1. For instance, melanoma-derived 
IL10 dampened the ability of dendritic cells to activate cytotoxic T cells and inhibited 
IFN production of NK cells, both at the origin of impaired antitumor immune 
responses201. Hence, monocytic macrophages conditioned by TGFβ1 might also be a 
source of IL10. MMPs are known to be TGFβ1-downstream targets in tumor and 
stromal cells202. Others have suggested that MMP production73 (including MMP245), 
but also IL10-secretion77 are functional features of TAMs. In contrast to this, the TAM 
marker CD163, and also other TAM-associated molecules such as CCL2 or 577 and 
MMP978, were not upregulated in TGFβ1 stimulated THP-1 cells. 
 
Although there was a strong tendency towards enhanced expression of Smad7, 
IL1B, SAA, PD-L1 and PAI-1 in TGFβ1-stimulated THP-1 cells, this effect was not 
significant. This might be explained through the context-sensitivity of the effects of 
TGFβ198, or by the experimental approach using THP-1 cells without pre-
differentiation. In this regard, it is notable that M-CSF as well as PMA, which are 




might lead to an overestimation of PAI-1 production by TGFβ1-stimulated, pre-
treated THP-1 cells, especially when comparing secreted levels with those of naïve 
HDF or melanoma cells. Nevertheless, although transcription of PAI-1 was not 
significantly increased, protein secretion of PAI-1 measured by ELISA was 
significantly enhanced in THP-1 cells in response to TGFβ1 stimulation (Figure 12). 
 
Taken together, my results suggest that TGFβ1 does not completely polarize naïve 
THP-1 cells towards TAMs, but upregulates molecules linked to immune evasion and 
matrix remodeling. 
6.2.4 TGFβ1 activates HDF to produce PAI-1 
HDF upregulate α-SMA expression in response to TGFβ1 treatment (Figure 8). This 
observation is consistent with expression signatures that have been reported for 
different models of CAFs, including TGFβ1-stimulated fibroblasts205 and melanoma 
CAFs in vivo66. Additionally, TGFβ1-stimulated HDF increased mRNA expression of 
IL6 in my experiments. In previous studies, CAF-derived IL6 was found to promote 
tumor cell migration and invasion in the context of melanoma59. Thus, tumor-derived 
TGFβ1 might contribute to the production of migratory signals by HDF. 
Upon TGFβ1 treatment, I found that HDF expressed significantly more SAA and PAI-
1. Consistently, others have characterized the expression and secretion of various 
factors in CAFs isolated from murine colorectal carcinoma, and found that SAA and 
PAI-1 were upregulated compared to normal fibroblasts145. Since colorectal tumors 
are known to produce TGFβ161, elevated expression of SAA and PAI-1 in this context 
could conceivably be induced by tumor-derived TGFβ1. Taken together, my results 
indicate that TGFβ1 activates naïve fibroblasts to produce molecules associated with 
melanoma progression, including PAI-1.  
 
Since both HDF as well as THP-1 cells upregulated PAI-1 in response to TGFβ1, the 
following paragraphs will consider the role of PAI-1 in my experiments and its 
functions in different contexts. 
 
6.3 Plasminogen activator inhibitor 1 
Plasminogen activator inhibitor 1 (PAI-1, encoded by the gene SerpinE1) is a serine 
protease inhibitor that represses tissue- and urokinase plasminogen activators (tPA 
and uPA)206. Additionally, SerpinE1 is considered to be a target gene of TGFβ1 
signaling171. Plasmin degrades the ECM either directly or through the activation of 
effector enzymes. Therefore, PAI-1 is a potent inhibitor of proteolysis in many 
processes, including wound healing, thrombosis, tissue growth and many others172. 
Additionally, PAI-1 has tumor-promoting roles beyond proteolysis inhibition, which will 




6.3.1 PAI-1 is present in melanoma 
In human melanoma sections, I observed expression of PAI-1 in both melanoma 
cells and stromal cells of the cancer microenvironment. Consistently, positive staining 
for PAI-1 has previously been found in human primary melanoma and cutaneous 
metastases176, fibroblasts and the ECM of murine melanomas207. Similar findings 
have also been made in other cancer types, with evidence that both CAFs and TAMs 
contribute to the PAI-1 content of the primary tumor milieu. In lung adenocarcinoma, 
PAI-1 staining correlated with that of α-SMA208, suggesting an important role for 
CAFs in PAI-1 production. The histological presence of PAI-1 in breast CAFs was 
linked to enhanced invasiveness209. In addition, an association between PAI-1 
staining and TAM infiltration in non-small cell lung carcinoma (NSCLC)210, and renal 
cell carcinoma211 has been reported, consistent with the co-localization of CD163 and 
PAI-1 in my experiments (Figure 10). Additional work will be required to determine 
whether these findings also hold true in melanoma. 
6.3.2 PAI-1 production by melanoma cells  
Figure 11 shows that some melanoma cell lines produced high levels of PAI-1 
compared to others. Interestingly, human melanoma cell lines that express high PAI-
1 levels were more likely to form lung metastases in mice compared to low-PAI-1 cell 
lines212. It is therefore notable that the cell lines with the highest PAI-1 levels in my 
experiments derive from metastatic sites (Mewo: lymph node metastasis161 and 
CRL1: cutaneous metastasis159). All other cell lines are from primary tumors (Table 
12) and had lower PAI-1 levels.  
6.3.3 PAI-1 production by HDF  
Unstimulated HDF produced high amounts of PAI-1 in my experiments (Figure 11). 
Others have also observed levels of secreted PAI-1 in unstimulated fibroblasts and 
melanoma cells that were approximately the same as those in my experiments213. 
Although PAI-1 was produced in relatively high amounts by naïve HDF, secretion 
was significantly increased by TGFβ1 stimulation. The absolute levels measured by 
ELISA were highest in TGFβ1-stimulated HDF (Figure 11 and Figure 12), suggesting 
an important role for these cells in PAI-1 production and amplification.  
 
Enhanced PAI-1 levels secreted by TGFβ1-stimulated fibroblasts have not yet been 
reported in the context of melanoma. Others showed that in situ-CAFs isolated from 
colorectal carcinoma61, OSCC214 and melanoma215 were sources of PAI-1, which is in 
line with my findings. In these studies, stimuli responsible for PAI-1 induction in 
fibroblasts were not investigated61, 214, 215. My findings suggest that TGFβ1 produced 
by these tumors61, 214, 216 might play a role. 
 
Taken together, these results suggest that fibroblasts represent an important but yet 





6.3.4 PAI-1 production by THP-1 cells 
The strong, but not significant upregulation of PAI-1 in TGFβ1-stimulated THP-1 in 
Figure 7 is in accordance with detected upregulation of this molecule in different 
models of TGFβ1-stimulated monocytes203, 217. Nevertheless, absolute levels of PAI-
1 in TGFβ1-stimulated THP-1 cells were lower (Figure 12) than in melanoma cell 
lines (Figure 11) or HDF (Figure 11 and Figure 12). It is known that other contextual 
factors such as glucocorticoids can enhance the responsiveness of macrophages to 
TGFβ1218, and the production of PAI-1 has been reported to be enhanced in 
monocytic cells exposed to glucocorticoids and TGFβ1203. Due to these context-
dependent effects of TGFβ1, melanoma-TAMs in situ may still be an important 
source of PAI-1. Therefore, positive PAI-1 staining in CD163-positive TAMs in Figure 
10 and the low absolute levels of PAI-1 in Figure 12 might not contradict each other. 
6.3.5 PAI-1 production is stimulated by TGFβ1-mediated crosstalk 
My results clearly show that TGFβ1 increases PAI-1 production in THP-1 cells as 
well as HDF. As TGFβ1 is produced by both tumor and stromal cells, these results 
suggest that TGFβ1-mediated crosstalk between these cellular compartments serves 
to amplify PAI-1 expression in the primary melanoma niche. Consistent with this 
notion, I found a positive correlation between plasma levels of PAI-1 and TGFβ1 in 
the blood from 22 melanoma patients. Cell lines with high TGFβ1 levels in my 
experiments (Mewo, CRL1, Figure 4) also expressed more PAI-1 (Figure 11) than 
cell lines with lower TGFβ1 mRNA levels (e.g. G361, C32, SKMel 28). This suggests 
that autocrine TGFβ1 signaling may also serve to increase local PAI-1 levels, which 
deserves to be investigated further. 
6.3.6 Functional roles of PAI-1 in melanoma and other tumors 
PAI-1 has been reported to have pleiotropic effects on tumor growth, angiogenesis, 
therapy resistance, invasion and metastasis. These effects will be described in detail 
in this section. 
 
PAI-1 can promote tumor cell proliferation directly. For example, PAI-1-
downregulation impaired the entry into the S-phase of the cell cycle through the 
depletion of cyclin D3/cdk4/6 and cyclin E/cdk2 in urothelial and cervical cancer cell 
lines. In this study, ectopic PAI-1 expression could also promote tumor growth in a 
mouse xenograft model219. 
 
PAI-1 is also thought to play a major role in cell migration, invasion and metastasis, 
since it influences cellular adhesion-deadhesion-cycles. Nevertheless, the literature 
suggests that PAI-1 can have both positive and negative effects on cell migration and 
invasion. On the one hand, the active form of PAI-1 dampens the activation of 
plasmin, inhibiting the degradation of the ECM206. Therefore, it might be argued that 
PAI-1 rather impedes tumor cell invasion. On the other hand, active, cleaved as well 




which promotes cell migration independently of plasmin220. LRP1 is a receptor 
involved in tumor progression, that is expressed (amongst others) in fibroblasts, 
macrophages, smooth muscle cells, and malignant cells221. Binding of PAI-1 to LRP1 
induces the internalization of cell surface bound integrins, resulting in cellular 
detachment from the ECM, which is necessary for migration222. 
 
Given these observations, the question arises whether the pro- or the antimigratory 
effects of PAI-1 predominate in the context of cancer. In OSCC, PAI-1 
overexpression enhances tumor cell migration by activation of the PI3K/AKT 
pathway223. Similarly, invasion and migration of colorectal carcinoma224 and glioma 
cells225 depends on PAI-1. In contrast to this, Humbert et al. found that PAI-1, derived 
from TGFβ-signaling, inhibited migration and invasion in several melanoma cell lines 
in vitro226. This latter study is the only one to report an inhibitory role for PAI-1 in 
tumor progression. The effect may be unspecific, as the authors reported that cell 
viability was significantly decreased after 48 h of TGFβ stimulation compared to 
unstimulated cells, which might at least partly explain impaired migration and 
invasion. In this study, decreased plasmin activity was implicated in the impaired 
migration and invasion. However, the researchers did not consider other target 
structures of PAI-1 involved in migration, e.g. LRP1. Nor the role of stromal PAI-1, 
neither the impact of PAI-1 on melanoma metastasis in vivo were considered in this 
study226.  
Other reports contradict the conclusion that PAI-1 has an inhibitory role in melanoma 
invasion and metastasis. For example, melanoma cell lines with enhanced metastatic 
potential in vivo have higher PAI-1 levels compared to non-metastatic cell lines227. In 
mice bearing B16-derived tumors, PAI-1 depletion limited melanoma metastasis174. 
In the same study, the inhibition of stromal PAI-1 had more pronounced effects on 
metastasis and angiogenesis compared to the depletion of tumor-derived PAI-1174. 
Therefore, it is important to consider the role of PAI-1 produced by tumor-associated 
stromal cells. Additionally, the effects of PAI-1 on migration, invasion and metastasis 
might also depend on the precise experimental conditions. 
 
In addition to effects on tumor cell migration and invasion, PAI-1 might play a role in 
stimulating the migration and recruitment of immune cells into the tumor 
microenvironment. For example, PAI-1 can cause macrophage migration into murine 
melanomas via binding to LRP1 and intracellular FAK-phosphorylation175. In another 
study, NSCLC-derived PAI-1 activated macrophages via TLR4, which recruited 
CD163-positive TAMs and induced TGFβ1 expression. TAM-derived TGFβ1 in turn 
stimulated tumor cells to produce more PAI-1, generating a feed-forward loop210. 
Therefore, it might be interesting to study the role of TGFβ1 and PAI-1 in a co-culture 
model of human melanoma cell lines and THP-1 cells. Others observed that the 
interaction between murine colorectal carcinoma cells and CAFs promotes the 
production of α-SMA, PAI-1 and TGFβ1 by CAFs. This over-activated the TGFβ1 





PAI-1 can exert both positive and negative effects on angiogenesis. The role of PAI-1 
in angiogenesis is dependent on the source (tumor or host cells) and the 
concentration of PAI-1. At lower levels, PAI-1 stimulates angiogenesis in murine 
melanoma, whereas it has antiangiogenic effects at high concentrations228. 
Proangiogenic roles of PAI-1 were also reported in various other tumors including 
breast cancer and NSCLC229. In mice bearing B16-derived melanomas, inhibition of 
PAI-1 reduced both angiogenesis and tumor growth174, but the mechanisms remain 
subject to further research. In another study, PAI-1 averted apoptosis of vascular 
endothelial cells by cleaving the surface bound apoptosis ligand FasL230. This may 
also contribute to the proangiogenic effects of PAI-1. 
 
In addition to promoting growth, PAI-1 plays a role in therapy resistance in different 
tumors. PAI-1 has been found to rescue OSCC from cisplatin-induced apoptosis223 
through activation of the PI3K/AKT pathway. Similar observations have been made in 
fibrosarcoma231, esophageal squamous cell carcinoma232 and NSCLC233. In 
melanoma, PAI-1 has been identified as one of the proteins upregulated in BRAFi 
resistant cell lines234, but the exact mechanisms explaining the role of PAI-1 in BRAFi 
resistance remain to be investigated. 
6.3.7 PAI-1 as a therapeutic target 
Since PAI-1 exerts many tumor promoting functions, therapeutic strategies targeting 
PAI-1 are currently being investigated. The small molecule PAI-1 inhibitor tiplaxtinin 
(=PAI-039) reduces the growth of urothelial carcinoma cell lines and xenografts219 as 
well as the cervical carcinoma cell line HeLa235. Additionally, it impairs the self-
renewal of tumor initiating cells in head and neck cancer by inhibition of SOX2 
expression236. Interestingly, SOX2 overexpression is induced in melanoma through 
TGFβ1, promoting invasion and metastasis237. Therefore, it might be interesting to 
test the effects of tiplaxtinin in melanoma. To date, only one study has investigated 
the effect of a PAI-1 inhibitor (SK-216) in melanoma. Here, SK-216 impaired tumor 
vascularization and growth in B16-derived melanoma xenografts174. Besides, there 
are numerous other small molecule inhibitors, small interfering RNAs and also 
natural compounds targeting PAI-1 that have been tested in breast cancer, colorectal 
carcinoma and other tumors229. Nevertheless, further studies are needed to identify 
side effects of these molecules. PAI-1 inhibition enhances plasmin-mediated 
fibribolysis206 and therefore might cause severe spontaneous bleeding. By inhibiting 
epithelial cell migration, collagen deposition and the differentiation of myofibroblasts, 
functional PAI-1 blockade impairs wound healing238. Further, most of the small 
molecule inhibitors targeting PAI-1 exhibit short plasma half-lives of around 2 to 3 
hours, and concentrations in the range of mmol/l were often needed in order to 
observe antitumor effects239. Nevertheless, recent approaches have been made to 
overcome these limitations. PAI-1 inhibitors are being modified to prolong their 




6.3.8 PAI-1: a potential diagnostic tool in melanoma? 
Importantly, I found that local PAI-1 upregulation was strongly associated with poor 
overall and progression-free survival in a cohort of melanoma patients (Figure 9). 
These are the first data to show a correlation between locally elevated levels of PAI-1 
and poor prognosis in melanoma. Consistent with these findings, PAI-1 has been 
associated with poor outcome in many tumors172. In lymph node negative breast 
cancer, it is already established as a marker for poor prognosis and high PAI-1 levels 
predict the benefit from adjuvant chemotherapy173. These data suggest that PAI-1 
may represent a useful prognostic and theranostic tool for assessment of melanoma 
patients. 
 
To date, few studies have considered the prognostic value of PAI-1 in melanoma. 
PAI-1 is upregulated in thick versus thin melanoma, or in atypical nevi and melanoma 
compared to benign nevi242. In cutaneous metastases, local PAI-1 levels were higher 
compared to primary melanoma lesions176. Increased PAI-1 levels were also 
observed in metastatic compared to nonmetastatic cell lines88. In 2002, a small study 
(including 18 patients with advanced melanoma, 12 cases with locally limited 
melanoma and 39 healthy controls) indicated that the active fraction of plasma-PAI-1 
might predict the metastatic risk of early stage melanoma243. Importantly, in this 
thesis, increased PAI-1 protein levels in melanomas from the TCGA cohort were 
associated with significantly worse overall and progression-free survival (Figure 9), 
further emphasizing a potential diagnostic role of PAI-1 in melanoma. 
 
The therapeutic landscape of melanoma is getting more and more complex and 
individualized. Therefore, there is an urgent need for new markers to facilitate clinical 
decisions in melanoma, e.g. in order to identify patients that might profit from a more 
expensive or more aggressive therapy, or patients that need to be monitored in 
shorter intervals. Therefore, based on the results of this thesis, I strongly recommend 







This thesis shows that melanoma cells condition fibroblasts and monocytic 
macrophages via TGFβ1 and SAA to create a tumor promoting milieu. TGFβ1 
enhanced PAI-1 production in both cell types, which was associated with poor 
outcome in melanoma patients. The following figure proposes a summarizing 
scheme of these results. 
 
 
Figure 14: Melanoma cells influence fibroblasts and monocytes through SAA and TGFβ1. Melanoma cells 
produce TGFβ1 and SAA, which have the capacity to condition fibroblasts and monocytes to create a tumor 
promoting milieu. Additionally, TGFβ1 induces PAI-1 in macrophages and fibroblasts. The most important sources 
of locally enhanced PAI-1 levels in this context are TGFβ1-stimulated HDF and melanoma cells. This local 
overexpression of PAI-1 significantly correlated with worse overall and disease-free survival in melanoma 
patients. PAI-1=plasminogen activator inhibitor 1, SAA=serum amyloid A, TGFβ1=transforming growth factor beta 
1, TLR4=toll-like receptor 4. 
SAA stimulation only had a significant effect on gene expression in THP-1 cells. In 
the main, SAA mediated these effects by activating TLR4. The upregulated genes 
have been implicated in melanoma invasion, matrix remodeling, angiogenesis, 
immune evasion and therapy resistance. These results emphasize an important role 
for monocytic macrophages in melanoma progression. 
 
TGFβ1 upregulated molecules linked to immune evasion and matrix remodeling in 
THP-1 cells. It also induced a CAF-like phenotype in HDF and promoted PAI-1 
production in both cell types. Currently, potential sources of enhanced PAI-1 levels in 
melanoma have been under-investigated. My results reveal that TGFβ1-activated 
stromal cells, especially fibroblasts, represent an important source of PAI-1, in 
addition to melanoma cells. 
 
Importantly, in melanoma patient samples of the TCGA cohort, I found that local 
overexpression of PAI-1 protein significantly correlated with worse overall and 
disease-free survival. This is the first cohort, in which a link between locally elevated 
PAI-1 and prognosis of melanoma patients has been investigated, underlining the 
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